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ABSTRACT OF DISSERTATION

PATHOGENESIS OF INFLUENZA A VIRUS: INHIBITION OF MONOCYTE DIFFERENTIATION
INTO DENDRITIC CELL
Dendritic cells (DC) are a heterogeneous population of hematopoietic cells that play a
versatile role in orchestrating immune responses against an array of invading
pathogens, including influenza virus. These cells reside in lymphoid organs as well as in
non-lymphoid tissues such as mucosal surfaces of respiratory and gastro-intestinal
system. Recent investigations have suggested that in the steady state, dendritic cells are
derived mainly from bone marrow precursor cells without a monocytic intermediate
whereas during inflammation or infection, monocytes readily differentiate to generate
monocyte derived dendritic cells (MoDC). The ability of virus infected monocytes to
differentiate into MoDC was investigated and the results demonstrated that in vitro
infection of monocytes with influenza virus impaired their development into MoDC. It
was also observed that influenza infection of monocytes, pre-treated with GM-CSF and
IL-4 for DC differentiation, was minimally-productive and non-cytopathic. In spite of
successful viral genome transcription, viral protein synthesis was restricted at an early
stage. However, despite of the limited replication, influenza virus infected monocytes
failed to develop the distinctive DC- like morphology when cultured with GM-CSF and IL4 as compared to their mock infected counterparts. Infected cells, after 4 days in
culture, expressed reduced amounts of CD11c, CD172a (myeloid marker), CD1w2 (CD1b)
and CCR5. Influenza virus infected monocytes also retained substantial non-specific
esterase activity, a characteristic for monocytes and macrophages. Antigen presentation
capability of infected cells was also affected as indicated by decreased endocytosis.
Production of IL-12, a pro-inflammatory cytokine and IL-10, a reciprocal inhibitory
cytokine, was coordinately modified in influenza virus infected monocytes in order to
arrest their differentiation into DCs. At least limited viral replication was necessary to
impede the differentiation process completely. However, viral NS1 protein activity, as
evidenced with a mutant influenza virus, was not essential for this inhibition. This
identified a new strategy by influenza virus to interfere with DC differentiation and
evade a virus specific immune response.
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CHAPTER I
INTRODUCTION AND LITERATURE REVIEW

Influenza is a term that was appropriated from Italian in the mid-1700s to
describe a disease that was believed to be the “influence” of miasma (bad air) and stars.
The causative agent of such “bad influences” and the pandemic that swept the world in
1918 could only be identified in 1931, when Dr. Shope was able to reproduce an
influenza like disease in healthy pigs by inoculating them with nasal wash from infected
ones (1). Since then influenza virus has been the focus of intense research which has
helped garner a very detailed knowledge about the molecular biology, pathogenesis and
immune responses of the virus.

1. Influenza virus
Influenza virus is a member of the viral family Orthomyxoviridae that includes
negative sense, single strand RNA viruses. The etymology of orthomyxoviridae can be
traced back to two Greek words: orthos (standard or correct) and myxa (mucus) which
thereby adeptly characterizes the ability of these viruses to bind and infect through the
host mucus membrane (2). This family of RNA viruses consists of five genera, namely
Influenzavirus A, Influenzavirus B, Influenzavirus C, Thogatovirus and Isavirus (3). The
first three genera each have one species or type: Influenza A virus, Influenza B virus and
Influenza C virus respectively. Theses three types of influenza viruses – A, B and C are
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distinguished based on the antigenic differences in their internal proteins, nucleocapsid
(NP) and matrix (M) protein. Influenza A virus has a broad host range that spans both
mammalian and avian species whereas influenza B virus can infect humans and seals,
and influenza C virus is contained within humans and swine. The genus Thogotovirus has
two species – Thogoto virus and Dhori virus. They mainly infect ticks but serological
evidence suggests that humans and other mammals are also susceptible. These tick
borne viruses are known to cause a febrile illness and encephalitis in humans. Infectious
salmon anemia virus is the only known virus within the genus Isavirus which has been
isolated from Atlantic salmons (3).

1.1. Influenza A virus
Influenza A virus is the primary causative pathogen for the seasonal, highly
contagious, acute respiratory illness in humans and other mammals. Influenza A viruses
are sub-divided into various sub-types on account of their antigenic identity of two
major surface glycoproteins – hemagglutinin (HA) and neuraminidase (NA). Sixteen
different HA and 9 NA variants have been identified so far (4). Wild aquatic birds
(waterfowl, ducks, geese, swan, gulls, terns etc.) are considered the natural reservoir for
all subtypes of influenza A virus. In wild aquatic birds, these viruses are benignly
adapted and cause only asymptomatic infection. Viruses in these reservoir hosts are
suggested to be in an evolutionary stasis, which is imperative for perpetual maintenance
of a consistent viral gene pool. However, over the years, different subtypes of influenza
A virus have successfully jumped from their natural reservoir hosts to other avian and
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mammalian species to establish clinical diseases (5). All currently known subtypes of
influenza A virus and their natural hosts are listed in table 1.1.
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Table 1.1: Natural hosts of influenza A viruses. The table indicates the subtypes of
hemagglutinin (HA) and neuraminidase (NA), and the hosts they have been identified
in.
Subtype

Predominant host

Subtype

H1

Human, pig, birds

N1

Human, pig, birds

H2

Human, pig, birds

N2

Human, pig, birds

H3

Birds, human, pig, horse, dog*

N3

Birds

H4

Birds

N4

Birds

H5

Birds, (human)

N5

Birds

H6

Birds

N6

Birds

H7

Birds, horse, (human)

N7

Horse, birds

H8

Birds

N8

Horse, birds, dog*

H9

Birds, (human)

N9

Birds

H10

Birds

H11

Birds

H12

Birds

H13

Birds

H14

Birds

H15

Birds

H16

Birds

Predominant host

Adapted from Lamb RA, Krug RM. Orthomyxoviridae:the viruses and their replication. In: Knipe DM,
Howley PM, Griffin DE et.al, editors, Fields Virology. 4th edition, 2001
* Science 2005; 310: 482–485
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1.2. Equine influenza virus
Equine influenza virus is one of the predominant causes of respiratory diseases
in horses worldwide (6). The first isolate of equine influenza virus was isolated from an
outbreak in Eastern Europe in 1956 and was indentified as an H7N7 subtype (influenza
A/equine/Prague/56). Subsequently, in 1963, another subtype (H3N8, influenza
A/equine/Miami/63) was isolated from horses in Miami, USA (7). Both subtypes
cocirculated among horses for about fifteen years, during which (around 1970s) equine
influenza viruses of the H7N7 subtype underwent reassortment with their H3N8
counterparts and acquired all the internal genes (i.e. PB2, PB1, PA, NP and NS) except
matrix gene (8). However, the H7N7 virus is believed to have ceased circulating after
1977 since when no new isolates of this subtype has been identified from horses (9).
The H3N8 virus continues to circulate and is responsible for all recent equine influenza
outbreaks. Based on their antigenic and genetic variability, H3N8 equine influenza
viruses are considered to have evolved into two divergent lineages: “American” and
“Eurasian” (10). Although initially they were grouped based on their geographical
distribution, some viruses from the American lineage were later isolated from the
United Kingdom. Equine influenza viruses from the American lineage have again been
sub-divided into three sub-lineages: South American, Kentucky and Florida (11). In 2004,
H3N8 equine influenza viruses from the American lineage, in an unprecedented manner,
were found to cross species-barrier to infect dogs (12). Since then some other H3N8
equine influenza viruses from the European lineage have also been isolated from pigs
which have raised a serious concern of probable host-expansion of these viruses (13).
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2. Structure of influenza A virus
2.1. Morphology
Influenza A viruses are small, pleomorphic particles. Spherical virions range from
80 to 120 nm in diameter while filamentous particles can measure up to several
micrometers in length. Fresh isolates are generally filamentous which changes into
almost entirely spherical morphology following several passages (14). The virion, under
electron microscope, shows two distinct layers – an evenly spaced outer zone (100 Å)
covering a densely packed inner material (60-100 Å) (15). The outer zone or envelope
consists of a host-derived lipid bi-layer within which the two surface glycoproteins,
hemagglutinin (HA) and neuraminidase (NA) remain embedded. M2 ion channels also
protrude through this envelope. Within the lipid envelope M1 matrix proteins form the
inner shell which encompasses the viral RNA genome. Each viral RNA segment remains
encapsidated by multiple nucleoproteins (NP) in a helical symmetry to form the
ribonucleoprotein (RNP) complex. Three RNA dependent RNA polymerase proteins (PB2,
PB1 and PA) stay attached to the end of each viral RNA segment of the RNP complex
(16).

2.2. Viral genome and encoded proteins
The genome of Influenza A virus (about 13.6 kb) consists of 8 single strand
negative sense RNA segments which altogether encode for eleven viral proteins.
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2.2.1. PB2
The PB2 gene of influenza A virus is 2341 nucleotide long and encodes for a 85.7
kDa polypeptide that constitutes one of the basic components of the heterotrimeric
viral polymerase complex (16). The PB2 subunit plays a crucial role in viral mRNA
transcription. It binds to the 5’-cap I structure (m7GpppNm) of host cell pre-mRNA
which is later cleaved, in a process called “cap snatching”, to prime viral mRNA synthesis
(17). The role of PB2 polymerase in viral RNA replication, although essential, is yet
obscure.

2.2.2. PB1
The PB1 gene of influenza A virus is the same in length as PB2 and it encodes the
second basic subunit (MW 96.5 kDa) of the viral polymerase complex. It serves as a
backbone that can bind to the other two polymerases as well as nucleoprotein (18, 19).
PB1 is the catalytically active RNA dependent RNA polymerase which is involved in
transcription initiation and elongation of messenger RNA (mRNA), complementary and
viral RNA (cRNA and vRNA, respectively) in a sequence specific manner (17, 20). Other
than the polymerase activity, PB1 also performs endonucleolytic cleavage of cellular
mRNA to generate capped RNA primers for initiation of viral mRNA synthesis (21).
Recently, a novel protein christened PB1-F2 has been identified to be expressed from an
alternate open reading frame (+1 ORF) of PB1 gene. This viral protein (about 87 amino
acids) localizes to the mitochondria and is emerging as an important player in influenza
virus pathogenesis through induction of apoptosis (22).
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2.2.3. PA
The third and the only acidic subunit (MW 84.2 kDa) of the viral polymerase
complex is encoded by the PA gene which has a length of about 2233 nucleotides (16).
Although particular functions of this polymerase protein have not been fully
characterized, PA is known to interact with PB1, possess weak protease activity and play
some yet unidentified role in both viral transcription and replication (18, 23, 24).

2.2.4. HA
The fourth largest gene (1778 nucleotides) in influenza genome encodes for a
membrane glycoprotein (MW 61.5 kDa monomer), hemagglutinin or HA (16). This major
surface antigen of influenza virus is responsible for receptor binding and membrane
fusion during viral entry into the cell. Each HA polypeptide has three sub-domains:
receptor binding, vestigial esterase and fusion domain (25). Biological activation of HA
requires three posttranslational modifications: (a) cleavage of the amino terminal signal
peptide (14-18 a.a.); (b) glycosylation and palmitoylation; and (c) proteolytic cleavage of
precursor HA0 into two disulfide-linked subunits, HA1 and HA2 (26). During maturation,
HA molecules also homotrimerize into a rod like structure with a globular head and a
stalk. The globular head accommodates the receptor binding site of the antigen.
Although sialyloligosacharides on cell membranes, in general, are recognized by all HA
subtypes, its host specificity somewhat depends on whether the sialic acid residue has a
α-2,3 or α-2,6 linkage to galactose. While most avian and equine influenza viruses favor
the N-acetylneuraminic acid α-2,3-galactose (NeuAcα2,3gal) linkage, human viruses
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preferentially bind to the N-acetylneuraminic acid α-2, 6-galactose (NeuAcα2,6gal)
linkage (27). Tracheal epithelial cells of pigs express both types of receptors which
render them a suitable “mixing vessel” for generation of avian-human reassortant
influenza viruses with pandemic potential (28). Once HA binds to its receptors on the
cell membrane, the virions are endocytosed into intracellular endosomes. In the acidic
pH of endosome, HA undergoes conformational changes to expose the N-terminal
fusion peptide of the HA2 subunit which brings viral and endosomal membranes
together to enable fusion (29). This membrane fusion allows release of viral RNP
complex into the cytoplasm to be imported into the nucleus for replication.

2.2.5. NP
The NP gene (1565 nucleotides) encodes a highly basic, single-strand RNA
binding protein (MW 56.1 kDa) called nucleoprotein (16). NP encapsidates viral RNA
molecules through their sugar-phosphate backbone to aid in their transcription and
replication (30). Assembly of NP with viral RNA also provides structural organization to
the RNP complex. This polypeptide contains at least two nuclear localization signals
(NLS1, a.a. 3-13 and NLS2, a.a. 198-216) and thereby plays a decisive role in intracellular
trafficking of RNP in and out of the nucleus (31, 32). NP also interacts with several viral
and cellular proteins. In addition to self-oligomerization, NP binds to the viral
polymerases (PB1 and PB2) and the matrix protein M1 (19, 33, 34). Cellular proteins that
have, so far, been indentified to interact with NP include importin alpha, F-actin, CRM1,
BAT1/UAP56 and Mx protein. Importin alpha, actin and CRM1 have functional
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association with NP for cellular trafficking of RNP complex (35-37). On the other hand,
UAP56 and Mx protein, through interactions with NP, up- and down-regulate viral RNA
synthesis, respectively (38, 39).

2.2.6. NA
The NA gene (1461 nucleotides) encodes for the second surface glycoprotein
(MW 50 kDa monomer) of influenza virus, neuraminidase (16). The major function of
this protein is enzymatic cleavage of sialic acids from cell surfaces to allow release of
newly synthesized progeny virions. It cleaves the α-ketosidic linkage that binds terminal
NeuAc5 to its sugar moiety (40). NA polypeptide is synthesized as a 454 a.a. monomer
which oligomerizes to form a mushroom shaped tetrameric protein. The box shaped
head contains the catalytic activity of the enzyme while the N-terminal stalk anchors it
into the viral membrane (41). Apart from releasing progeny viruses, it also removes
sialic acid residues from the carbohydrates on viral membrane glycoproteins to prevent
virus self-aggregation (42). It has also been suggested to remove mucins to lower
viscosity and allow the virus access to the epithelial cells. However, it does not play any
role in attachment, replication or assembly of the virus (43).

2.2.7. M
The M gene (1027 nucleotides) encodes two viral proteins: the matrix protein
M1 (MW 27.8 kDa) and ion channel protein M2 (MW 11 kDa). M1 is the most abundant
viral protein that underlies the lipid envelope to provide structural rigidity. It is also
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believed to interact with the cytoplasmic tails of HA and NA (44). M1 binds to vRNPs
through its C-terminal domain for their nuclear-cytoplasmic transport (45, 46). It also
acts as a driving force for recruiting and assembling viral and host components during
budding of the virus (47). The second protein, M2, is expressed from a spliced mRNA
derived from M RNA segment. It is a type III integral membrane protein with a short
ectodomain, a transmembrane domain and an endodomain or cytoplasmic tail (48). M2
primarily functions as a tetrameric ion channel that allows influx of protons from the
acidic endosome, leading to conformational changes and eventually uncoating of viral
RNP complex (49).

2.2.8. NS
The smallest gene, NS (890 nucleotides), also encodes two viral proteins: NS1
(MW 26.8 kDa) and NEP (formarly NS2, MW 14.2 kDa). Although NS1 is not incorporated
as a structural component into the virion, it is abundantly synthesized during virus
replication. NS1 is a multifunctional protein which not only assists in viral replication but
also defends against cellular anti-viral responses. It is synthesized as a 230-237a.a. long
polypeptide which likely forms dimers (50). NS1 protein is known to interact with the
viral replication complex (RNP) and its role has been suggested in replication of vRNA as
well as selective enhancement of viral mRNA translation (51-53). NS1 protein is
functionally divided into two domains: N-terminal RNA-binding domain (RBD, a.a. 1-73)
and C-terminal effector domain (a.a. 74-230) (54, 55). The RBD can nonspecifically bind
to dsRNA and thereby prevent activation of several transcription factors (NF-kB, IRF-3,
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JNK/AP-1) required for IFN-α/ß induction (56-58). More recently, it has been shown
that, RIG-I, a cytoplasmic sensor for pathogen associated molecular patterns like ssRNA,
is also inhibited by NS1 to block interferon induction (59). The RBD of NS1 also plays a
potential role in inhibiting another cytoplasmic, dsRNA binding antiviral protein: 2’-5’
oligoadenylate synthatase (OAS/RNaseL) (60). On the other hand, the effector domain
of NS1 antagonizes the immune response at the post-transcriptional level through
interaction with a number of cellular proteins. It can bind to two essential components
of the cellular pre-mRNA processing machinery, namely, the 30 kDa subunit of cleavage
and polyadenylation specificity factor (CPSF 30) and the poly (A)-binding protein II
(PABPII); and this leads to accumulation of defective cellular pre-mRNAs (uncleaved or
with short poly-A tail) in the nucleus of infected cells (61, 62). Interestingly, however,
inhibition of CPSF30 by NS1 does not affect influenza virus mRNA processing since
polyadenylation of influenza mRNA is independent of this cellular protein. The effector
domain is also known to inhibit activation of serine/threonine protein kinase R (PKR), an
anti-viral protein that can diminish viral protein synthesis (63). Finally, in an attempt to
thwart the development of adaptive immune response, NS1 protein inhibits maturation
and migration of dendritic cells leading to dysfunctional T cell stimulation and decreased
cytokine production (64).
The second protein, NEP (nuclear export protein), is expressed from a spliced
mRNA of NS RNA segment and is present in virions in a phosphorylated form (65). The
main function of this protein is, in association with M1, transport of viral
ribonucleoproteins from the nucleus to the cytoplasm. A leucine/methionine rich
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nuclear export signal in the N-terminus is thought to be vital for this function (66). As for
the mechanism of nuclear export, NS2 protein has been shown to interact with several
nucleoporins as well as the nuclear export receptor, Crm1 (66, 67). Recently, it has also
been suggested to play a role in regulation of viral RNA transcription and replication
(68).

3. Replication cycle of influenza A virus
One complete replication cycle of influenza A virus can be divided into several
stages: attachment, entry, fusion and uncoating, genome transcription, viral protein
synthesis, assembly and egress/budding. Viral attachment to cell surface receptors
(sialic acid) is mediated by hemagglutinin (HA) protein which has been described in
section

2.2.4.

Following

attachment,

virions

are

endocytosed

into

cellular

compartments. Several endocytic mechanisms including clathrin-coated pits as well as
clathrin-caveolin independent pathways have been described for influenza virus entry
(69, 70). Low pH within the endosome brings about conformational changes in HA
protein leading to fusion of viral and endosomal membrane resulting in release of viral
RNP complex into the cytoplasm. Viral RNAs along with their replicases are then actively
transported into the nucleus. Nuclear localization signals on the nucleoprotein are
essential for this transport (31, 32). Once inside the nucleus, negative sense viral RNA
segments are transcribed into mRNAs in a cap-dependent manner. These mRNAs are
thereafter transported out into the cytoplasm for viral protein synthesis. Nucleoprotein
(NP) and NS1 protein are preferentially synthesized at the early stage of viral infection
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while synthesis of HA, NA and M1 is deferred to a later stage (71). After certain cycles of
viral protein synthesis, the transcription machinery switches from mRNA to cRNA
(complementary to viral genomic RNA) and vRNA (viral genomic RNA) synthesis.
Following viral replication, RNP complexes are assembled in the nucleus and are
exported out to the cytoplasm by M1 and NEP (46, 66). In the final step, the viral
genome and proteins are assembled on the plasma membrane and newly synthesized
virions are released from the apical surface of epithelial cells.

4. Pathogenesis of influenza A virus
The outcome of influenza virus infection varies with different virus subtypes and
the susceptible host. In wild aquatic birds which serve as the natural reservoir hosts for
influenza, viral replication is largely restricted to the gastro-intestinal tract and the
infection is generally asymptomatic (72). In other birds such as domestic poultry, turkey,
quail and pheasant, influenza infection is normally non-fatal; with the exception of some
highly pathogenic H5 and H7 subtypes, which have run havoc among chickens in recent
years (73). In mammalian hosts (swine, equine, human), influenza virus is mainly a
respiratory pathogen with disease severity ranging from asymptomatic to severe
systemic fatal infection. The virus primarily infects and replicates in the ciliated
columnar trachea-bronchial epithelium and then spreads to the lower respiratory tract
or sometimes to systemic organs. Normal manifestations of the seasonal illness include
fever, headache, cough, sore throat, anorexia and malaise. Pathogenesis of influenza
virus, as described here, can mainly be ascribed to its ability to shut off host cell protein
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synthesis, induce apoptosis and regulate several cellular transcription systems in order
to avoid the host immune response. The PB2 polymerase protein, as mentioned in
section 2.2.1., binds to host cell mRNA cap structures in the nucleus and cleaves them to
prime viral mRNA synthesis (17). The decapped cellular mRNAs then get degraded.
Nuclear export of cellular pre-mRNAs that escape “cap snatching” is blocked by NS1
protein by inhibiting their splicing (74). Productive replication of influenza virus in
respiratory epithelium results in apoptotic cell death (75). At least three viral proteins,
NA, NS1 and PB1-F2, are known to regulate apoptosis of infected cells (22, 76, 77).
Influenza virus infection activates several transcription factors which in turn induce
expression of a number of anti-viral cytokines and chmokines genes. Viral NS1 protein,
as explained in section 2.2.8., plays an important role in regulating those cellular
transcription systems. The NS1 protein is a known antagonist of IFN α/ß production (56).
It also inhibits maturation and cytotoxic T cell stimulation of dendritic cells and thereby
stalls the development of an adaptive immune response against the virus (64). However,
apart from these general mechanisms of cellular pathogenesis, highly virulent influenza
viruses possess many other features to develop severe fatal disease.
Highly virulent human and avian influenza viruses, which have the potential to
cause a human pandemic, exhibit several other pathogenic characteristics.
Experimental infection of monkeys with virulent H5N1 influenza virus (human isolate)
produces severe lesions including necrotic broncho-interstitial pneumonia, damaged
respiratory epithelium and intra-alveolar hemorrhage as well as necrotic lesions in
lymphoid organs, liver and kidney (78). Virulence of these viruses has been attributed to
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several factors. One major determinant of influenza virus pathogenesis is the
cleavability of precursor hemagglutinin protein (79). Proteolytic cleavage of precursor
hemagglutinin (HA0) protein into two disulfide linked subunits, HA1 and HA2, is a
prerequisite for successful fusion of viral and host endosomal membranes and therefore
is necessary for viral infection. Low pathogenic avian influenza viruses and most
mammalian influenza viruses except H7N7 equine influenza viruses, have a single
arginine residue at the cleavage site between HA1 and HA2 subunits (80, 81). This
requires serine family proteases for activation, therefore restricting their replication to
the respiratory tract (82). On the other hand, highly pathogenic avian influenza viruses
possess multiple basic amino acid residues at the cleavage site which is recognized by
several ubiquitous proteases such as furin and PC6 (80, 83). This allows them to infect
systemic organs other than lungs and thereby enhances their pathogenicity. Viral
neuraminidase (NA) has also been suggested to play a role in it virulence. Lack of a
carbohydrate side chain on NA in some viruses such as WSN/33 (H1N1) allows them to
sequester cellular plasminogen which in turn facilitates the cleavage of hemagglutinin
(84). The high replication ability of the 1918 pandemic influenza strain in cell culture in
absence of trypsin has also been attributed to its neuraminidase protein (85). Another
virulence factor and pro-apoptotic protein, PB1-F2, from this pandemic strain not only
enhances the pathogenecity of the virus but also exacerbates the subsequent bacterial
infections (Streptococcus pneumonia) by increasing cytokines and chemokines release
(86). Additionally, the carboxy-terminus of the NS1 protein from highly virulent H5N1
human isolates has been found to possess a PDZ binding motif (Glu-Ser-Glu-Val, ESEV)
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which can interfere with cellular signaling pathways responsible for protein trafficking
and maintenance of cell morphology (87). Pathogenesis of influenza virus is a
profoundly studied field and several other viral and host factors are yet under
investigation that may elucidate important aspects in the disease progression and
virulence of this virus.

5. Immune response to influenza A virus
In the wake of a seasonal influenza infection, an immune-competent host
generates a robust anti-viral response. This anti-viral immunity consists of both innate
and adaptive responses that enable containment and clearance of the viral infection in
about a week’s period.

5.1. Innate immune response
The innate immunity is a relatively non-specific response that constitutes the
first line of defense against an invading pathogen. This defense mechanism is
considered primitive as it has remained conserved among mammals, lower vertebrates
and invertebrates. However, its does not provide a memory or long-lasting protection.
The innate immune system is comprised of physical barriers, soluble chemical factors
and cellular components.
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5.1.1. Physical barriers
The epithelial surfaces form the first physical barrier to any bacterial or viral
infections. Mucins produced by respiratory epithelial cells trap bacteria or virus particles
while movement of broncho-pulmonary cilia clears them out of the airway.

5.1.2. Soluble antimicrobial mediators
Pathogens that successfully breach this barrier are neutralized by soluble
antimicrobial factors, such as lysozyme, lactoferrin and defensins. Human alphadefensins, for instance, are short cationic antimicrobial peptides of neutrophils that can
inhibit influenza virus replication (88). Another well characterized heat liable, enzymatic
mediator of the innate immunity is the complement system. Its antimicrobial activity is
primarily mediated through opsonization which activates neutrophils and mast cells to
phagocytose and lyse complement bound pathogens. Its important role in anti-viral
immunity was established when complement deficient mice were found to be more
susceptible to influenza virus infection (89). Complement present in human serum can
neutralize influenza virus and in vivo experiments show that in association with natural
antibody (IgM), complement can provide protective immunity in influenza naïve hosts
(90-92).

5.1.3. Pattern recognition receptors
The innate immune system maintains an evolutionarily preserved set of
receptors that distinguishes self from non-self (microbial) antigens based on their highly
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conserved structural features called pathogen associated molecular patterns (PAMPs).
PAMPs can consist of sugar moieties, lipids, nucleic acids or combinations of any of
these. The receptors that recognize them are, therefore, known as pattern recognition
receptors (PRRs).
Collectins, the C-type lectin bearing members of the collagen family, are
important soluble PRRs of the innate immune system. Among the nine members that
have been identified so far, mannan-binding lectin (MBL) and surfactant proteins A and
D (SP-A and SP-D) are the most studied for their role in host defense against infectious
agents. MBL is secreted into the bloodstream mainly by the liver whereas SP-A and SP-D
are predominant among alveolar spaces in the lung (93, 94). They, in general, bind to a
variety of carbohydrate residues on pathogen surfaces and thereby activate cells to
respond by way of agglutination, complement activation, opsonization and phagocytosis
(95, 96). During influenza infection, human MBL can bind to both HA and NA on virus
particles and thereby neutralize and contain the viral spread (97). Similarly, the
protective mechanism of SP-A and SP-D in influenza infection involves direct virus
neutralization, opsonization or enhanced uptake and hydrogen peroxide production by
neutrophils (98, 99).
In the past decade, scientific knowledge about cellular sensing of a microbial
invasion was revolutionized by the discovery of toll-like receptors (TLRs). The first toll
protein was identified in Drosophila as a mediator of its antifungal immunity (100). This
was soon followed by the characterization of its mammalian homologue in humans,
hToll or currently recognized as TLR4 (101). Since then 13 receptors (TLR 1 -13) have
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been discovered in mammals. Among them, TLR10 is expressed in humans but not
mouse whereas TLR11 has only been found in mouse. Except for TLR3, 7, 8 and 9 which
are found within endosomes, all others are expressed on the plasma membrane (102).
All of these TLRs are type-I transmembrane glycoproteins with a leucine rich
extracellular domain and a cytoplasmic domain containing toll/interleukin-1 receptor
(TIR) homology. The extracellular structure binds to its respective ligands and the
intracellular domain is responsible for passing on the activating signal downstream
(103). TLR2 which forms heterodimers with TLR1 and TLR6 binds to tri- or diacylated
lipopeptides respectively. TLR3 recognizes dsRNA molecules while lipopolysaccharide
(LPS) acts as a ligand for TLR4. Bacterial flagellin binds to TLR 5. TLR7 and 8 primarily
sense viral ssRNA molecules whereas unmethylated CpG containing bacterial DNA
motifs bind to TLR9. Uropathogenic bacteria can be detected by TLR11. Specific ligands
for TLR10, 12 and 13 have not been identified yet (102). Binding of specific microbial
components to TLRs results in their activation. All of these receptors use a common
signaling pathway. Following recognition of a microbial motif, toll like receptors form
dimers – most of them form homodimers, but TLR2 uses TLR1 or TLR6 to form
heterodimers. Based on the adaptor molecules used, their signaling pathways are
generally classified into two categories: (a) MyD88 dependent pathway and (b) MyD88
independent pathway. All but TLR3 utilize the MyD88 dependent pathway to activate
transcription factor NF-kB which in turn leads to expression of various inflammatory
cytokine genes. On the other hand, TLR3 and in part TLR4 activation promotes
expression of interferon genes through stimulation of a different transcription factor
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called IRF3. However, activation of either pathway results in production of proinflammatory cytokines and IFN which in turn lead to the development of antigen
specific adaptive immunity (104). TLR7 expressed on plasmacytoid dendritic cells can
detect influenza virus genomic RNA (105). Similarly, TLR3 which is constitutively
expressed in pulmonary epithelial cells mediates activation and production of cytokines
during influenza virus infections (106). More recently, an important role of the TLR7MyD88 signaling pathway has been suggested even for the development of a virus
specific adaptive (CD8 + T cell) immune response (107).
While TLRs are efficient at detecting pathogens either on cell surfaces or inside
endosomes, some other recently identified PRRs can sense PAMPs in the cytosol: RIG-1
(retinoic acid inducible gene -1), MDA-5 (melanoma differentiation associated gene -5),
NOD-1/2 (nucleotide binding oligomerization domain-1/2) and other C-type lectins e.g.
dectin-1 [reviewed in (108, 109)]. Although both RIG-1 and MDA-5 recognize dsRNA
from viruses, RIG-1 was found to play a more important role in interferon signaling
during influenza virus infection (110). Similarly, NLRs (NOD like receptors) can also
recognize viral RNA and are necessary for activation of inflammasomes (multiprotein
complex responsible for activation of inflammatory processes) as well as development
of adaptive immunity (111, 112).

5.1.4. Cells of innate immune system
Cells of monocytic lineage such as macrophages, dendritic cells and natural killer
cells constitute the cellular compartment of innate immune system.
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5.1.4.1. Macrophages
Macrophages are important effector cells of the innate immune system. In
steady state or inflammation, circulating monocytes differentiate to generate tissues
macrophages. Depending upon their anatomical localization, macrophages have been
given different names, for example, alveolar macrophages in the lungs, microglia in the
CNS, Kupffer cells in the liver etc (113). These are very potent phagocytic cells and their
primary function is maintenance of tissue homeostasis by clearing out cellular debris,
apoptotic as well as necrotic cells. However, upon activation, they produce large
amounts of inflammatory cytokines and chemokines. Alveolar macrophages have been
found susceptible to influenza virus infection in vitro and the infection results in quick
cytopathic death of these cells (114). Influenza infected macrophages show an increased
transcription level for an array of anti-viral cytokines including IL-1 beta, IL-6, TNF-alpha
and IFN α/ß (115). They also produce chemokines such as RANTES, monocyte
chemotactic protein -1 (MCP-1) and macrophage inflammatory protein -1 alpha (MIP 1α) which further attract more mononuclear cells to the site of infection to aid in viral
clearance (116).

5.1.4.2. Dendritic cells
Dendritic cells (DC) are a unique population of cells that play a pivotal role in
molding immune responses against invading pathogens. These are a sparsely distributed
heterogeneous population of hematopoietic leukocytes with diverse phenotypes and
functions. In 1973, R. M. Steinman and Z. A. Cohn first observed a population of large
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stellate cells with distinct morphological properties in mouse spleen and described
them, due to their veiled structure, as “dendritic cells” (117). Apart from lymphoid
organs (spleen, lymph nodes), DCs are also found in non-lymphoid tissues such as lungs,
epidermis (langerhan’s cell), dermis (interstitial cell) etc. Some characteristic features of
DCs are: [a] DCs are plastic adherent, low density cells with poor viability in culture. [b]
They have few lysosomes and lack Fc receptors. [c] They are the most potent antigen
presenting cells (APC) and efficient activators of T lymphocytes. A very small number of
DCs pulsed with little amount of antigen can stimulate a large number of T cells. They
can stimulate proliferation of both CD4+ and CD8+ T lymphocytes (118).
Because of their heterogeneity, the origin of DCs has been a highly debated topic
in recent years (Figure 1.1). In the bone marrow, DCs can originate from either Flt3+
(FMS like tyrosine kinase 3) common myeloid (CMP) or common lymphoid progenitor
(CLP) cells (119, 120). CMPs and CLPs differentiate into macrophage-DC progenitors
(MDP, Flt3+M-CSFR+CX3CR1+) and common DC progenitors (CDP, Flt3+CD115+)
respectively which enter into the bloodstream and later migrate into secondary
lymphoid organs to give rise to DCs. However, in the periphery during inflammation or
infection, monocytes can also differentiate to generate inflammatory DCs (121). In
human and mouse, based on phenotypic surface markers expressed and specialized
functions, DCs have been categorized into several sub-types. Broadly, in lymphoid
tissues, DCs are often classified as either conventional DCs (cDC), potent antigen
presenting cells or plasmacytoid DCs (pDC), producers of type I interferon (122).
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Figure 1.1: DC ontogeny in mice.
Reproduced with permission from Nature Immunology 8, 1199-1201 (2007)

24

Immediately after differentiation from hematopoietic precursors, DCs circulate
throughout the periphery in “immature” forms and scan the body for any self antigen
(tolerance) or invading pathogens (immunity). Once encountered, highly adept
“immature” DCs capture the antigen by macropinocytosis, phagocytosis or receptor
mediated endocytosis (123). This antigen capture initiates a series of phenotypic and
biochemical changes in DCs called “maturation”. Maturation of DCs is characterized by
reduced antigen capturing ability, increased surface expression of co-stimulatory
molecules, i.e. CD68, CD83, CD86, MHC I, MHC II and production of cytokines and
chemokines. Activation of the Interferon signaling pathway by microbial PAMPs has
been shown to stimulate this maturation process (124). Initiation of maturation drives
DCs to migrate to secondary lymphoid organs where they present the captured antigens
to lymphocytes for proliferation and functional activation. Depending on the invading
pathogen, DCs can present antigen on either MHC I or MHC II to a particular subset of
lymphocytes. For intracellular microbes like viruses, DCs present antigens on MHC I
which is recognized by CD8+ T cells. This results in vigorous proliferation of cytotoxic T
cells that can in turn lyse infected cells. On the other hand, extracellular pathogens are
taken up into endosomes from where they are presented on MHC II molecules leading
to CD4+ T cell mediated immune response (125). While peptides mounted on MHC
molecules provide the “signal 1” to T cells, “signal 2” or “co-stimulation” is delivered by
interactions of CD80/86 with CD28 on T cells. Signal 3, a term coined very recently, is
used by dendritic cells to promote T cell differentiation into specific effector cells, e.g.
cytotoxic or Th1 or Th2 cells (126). Polarization of Th1 or Th2 type immunity is
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determined by pathogen primed DCs through production of several DC derived
polarizing factors. IL-12 primarily is considered to be the Th1 type cytokine whereas IL-4
(in absence of IL-12) drives helper cells towards Th2 type immunity (127). Th2 cells
synthesize IL-5 and IL-4 which in turn stimulate B cells to produce appropriate
antibodies against the invading pathogen.
Equine dendritic cells, when cultured in vitro from blood monocytes with GMCSF and IL-4, exhibits similar morphological and cytochemical characteristics as of
human DCs (128). They express similar pattern of phenotypic surface makers as human
DCs and are also potent stimulators of T cells as observed in mixed lymphocyte
reactions (129). When activated by maturation stimuli such as inactivated E.coli,
immature equine DCs can mature; express maturation markers on their surface and
produce enhanced cytokines as well (130).
The pivotal role of DCs in the innate and adaptive immune response makes them
a major target for bacteria, viruses and other pathogens. Although the in vivo role of
DCs in influenza infection is not completely understood, several in vitro studies have
helped in unraveling some of the mysteries. It is not known whether influenza naturally
infects DCs in vivo. However, ex vivo generated DCs of both human and mice origin can
be successfully infected by influenza viruses (131, 132). However, the infection is nonproductive – despite the synthesis of viral proteins, little progeny virus is produced. The
infection is also non-toxic as infected DCs do not show any cytopathic effect or
apoptosis (131). Influenza virus infected DCs can initiate a strong proliferation of
cytotoxic CD8+ T lymphocytes (133). Activated DCs also secrete antiviral cytokines (IFN
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α/ß) and promote a Th1 type immune response by stimulating IFN γ production by CD4+
T cells (134). The NS1 protein of influenza virus, as mentioned earlier, has been shown
to inhibit the maturation of infected immature DCs and thereby prevent development of
an adaptive immune response (64).
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Table 1.2: CD antigens.
CD antigen

Cellular expression

Functions

Expression on
DC

CD1b

Cortical thymocytes,
Langerhans cells,
Dendritic cells

Antigen (lipid)
presentation

Thymocyte subsets,
TH1 and TH2 cells,
monocytes,
macrophages
Thymocyte
subsets,
cytotoxic T cells

Co-receptor for MHC
class II molecules

+/-

Co-receptor for MHC
class I molecules

+/-

CD11c

Myeloid cells

Binds fibrinogen

++

CD14

Myelomonocytic cells

Receptor for LPS and
LPS binding protein

-

CD86

Monocytes, activated B Ligand for CD28 and
cells, dendritic cells
CTLA4

+

CD172a

Myeloid cells

Adhesion molecule

+++

MHC I

Nucleated cells

Antigen presentation

++

MHC II

T cells, B cells,
macrophages, dendritic
cells

Antigen presentation

++

(CD1w2 homolog)

CD4

CD8

+

th

Adapted from Janeway’s Immunobiology, 7 ed.
J. Exp. Med. Vol. 179 April 1994, 1109-1118
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5.1.4.3. Natural killer cells
Natural killer (NK) cells are a population of large granular lymphocytes that are
particularly adept at lysis of target cells without prior sensitization. They are found
abundantly in blood, liver, spleen, lymph nodes and other non-lymphoid organs such as
pregnant uterus. They circulate in the body as “resting” cells containing a pool of
constitutively expressed high levels of IFN γ, perforin and granzyme B mRNA transcripts
(135, 136). However, these “resting” cells require activation by IFNα/ß or other proinflammatory cytokines (IL-2, IL-12, IL-15 and IL-21) to acquire their cytolytic effector
functions (137). Following activation, they produce an array of cytokines (TNF-α, IFN-γ
etc.) and cytolytic mediators (perforins, granzymes). Activated NK cells kill target cells
either by creating pores on membranes with perforins and granzymes or by activating
apoptotic signaling in the target cells (137). Since these naturally primed killer cells are
broadly reactive and have the potential to kill harmful target cells as well as naïve host
cells, their activity is strictly regulated through a series of activation and inhibitory
receptors (138). The importance of NK cells in the innate immunity against influenza
virus is evident by the large number of these cells that accumulate in the lungs of
infected mice and any depletion or mutation of NK cell receptors can seriously
exacerbate the illness (139, 140). NK cells recognize influenza HA proteins through direct
interactions with its receptors called NKp46 and NKp44 (141, 142). Recent studies have
also shown that use of an adjuvant that activates NK cells can boost the immunogenicity
and protective efficacy of influenza vaccines (143).
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5.1.5. Cytokine system
Cytokines are a diverse family of small proteins that are produced in response to
different stimuli and exert their functions through binding of specific cellular receptors.
They play an important role during viral infections.
Interferons are a type of cytokine that are produced during viral infections and
are aptly named so because of their ability to interfere with viral replication. IFN-α and
IFN-ß are type I interferons whereas IFN-γ is often called as type II. Although most
nucleated cells can produce type I interferons, plasmacytoid DCs (pDCs) are considered
as the specialized producers of these cytokines (144). They bind to a common cellsurface interferon receptor and activate transcription of several genes (ISG, interferon
stimulated genes) through Janus family tyrosine kinase pathway. Several protein
products of ISGs have anti-viral activities. For example, oligoadenylate synthetase (OAS)
helps in degradation of viral RNA while protein kinase R (PKR) has an inhibitory effect on
viral protein synthesis. Another ISG protein, Mx is associated with resistance against
influenza infection (145). On the other hand, IFN-γ is primarily produced by T cells and
NK cells and its function is to activate macrophages.
Interleukins (IL) constitute another group of cytokines that are mainly produced
by leukocytes. A number of interleukins have been identified so far which can act locally
or systemically to exert divergent effects on both innate and adaptive immune
responses. Some of them such as IL-1, -6 and -12 act as “pro-inflammatory” cytokines
whereas IL-10 exhibits an “anti-inflammatory” activity. They bind to their specific
receptors and activate the JAK-STAT signaling pathway to modulate cellular functions.
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5.2. Adaptive immune response
The adaptive immunity is an antigen-specific, cellular defense system that
requires activation by the innate immunity to eliminate a microbial infection. Although it
develops late into an infection, it can provide a strong memory or lasting protection
against the same invading pathogen. The adaptive immune system is predominantly
comprised of T and B lymphocytes.

5.2.1. T cells
T lymphocytes constitute an important effector arm of the adaptive immune
response. Precursors of T lymphocytes develop from hematopoietic stem cells in the
bone marrow and then migrate to the thymus for complete maturation (146). During an
infection, APCs circulating in the periphery capture the antigen and bring them to the
thymus where they present the antigen to T cells which in turn undergo “clonal
expansion” to produce large numbers of progeny T cells. Depending on the surface
molecule expressed on them, activated T cells perform different tasks to eliminate the
invading pathogen.

5.2.1.1. CD8+ T cells
Antigens presented on MHC class I molecules can be recognized by CD8+ T cells.
Once activated, they become cytotoxic T lymphocytes (CTL) which are programmed to
kill infected cells. Several mechanisms including calcium dependent perforin exocytosis
and Fas mediated apoptosis have been suggested as the means by which CTLs destroy
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infected cells (147). During influenza infection, CTLs play a critical role in viral clearance.
Initial activation of naïve CD8+ T cells in lymph nodes occurs within the first 3 days of
infection. Antigen primed CD8+ T cells thereafter start to divide, acquire their cytotoxic
activity and exit through draining lymphatic vessels to reach the lungs (148). Six days
post infection, almost 70 % of lung-infiltrating lymphocytes are found to be cytotoxic.
Most (90%) of these CTLs can recognize epitopes from either HA or NP viral protein
(149). Viral antigen stimulated CTLs produce large amount of IFN-γ and TNF-α which
help in recruiting leukocytes to the site of inflammation (148). Following viral clearance,
memory CTLs down-regulate transcription of cytotoxic proteins and circulate in
lymphoid (spleen) and non-lymphoid (skin/lungs) tissues (150). However, when reexposed to the same antigen, memory CTLs can rapidly initiate their cytotoxic functions
(151).

5.2.1.2. CD4+ T cells
CD4+ T lymphocytes are often referred to as helper T (T h) cells as their primary
function is to assist B lymphocytes in producing antibodies against microbial infections.
These T lymphocytes recognize antigens presented on MHC class II molecules and
depending on the type of pathogen, they can differentiate into either Th1 or Th2
phenotype. Th1 type CD4+ T cells produce IFN-γ and TNF-α, and stimulate cytotoxicity of
macrophages and CTLs; whereas Th2 type cells secrete IL-4 and IL-5 and promote
neutralizing antibody production by B cells (152). Influenza virus infection activates DCs
to produce IL-12 which in turn drives CD4+ T cells towards Th1 phenotype. During
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influenza virus infection, CD4+ T cells provide protection in a B cell dependent manner,
although they themselves possess some cytotoxic (perforin) activity too (153). CD4+ T
cells are also necessary for optimal recruitment of CD8+ T cells to the infected lungs and
subsequent viral clearance by CTLs (154). Following recovery or live virus clearance
activated CD4+ T cells progress to become memory cells. However the number of CD4+
memory T cells decline much faster than their CD8+ counterparts (155).

5.2.2. B cells
B cells are a lymphocyte subpopulation responsible for eliciting the humoral
immune response during an infection. In mammals, B cells originate in the bone marrow
and mature in secondary lymph nodes or spleen. Terminally differentiated B cells are
called plasma cells whose primary function is to produce antibodies to specific antigens
(156). However, they can also uptake, process and present antigens to T cells in an MHC
restricted manner (157). Neutralizing antibodies produced by B cells during an influenza
infection have an important protective role and are therefore the main targets of
vaccine induced immunity. Development of humoral immunity to an influenza infection
consists of an early rise in IgM antibody titer followed by their affinity maturation and
immunoglobulin class-switing to IgG, IgA and IgE antibodies (158). Mice that are
deficient in B cell and therefore incapable of producing are 50 – 100 times more
susceptible to a lethal influenza infection and they show a higher mortality rate when
challenged with a pathogenic PR8 strain of influenza (159, 160). On the other hand,
passive transfer of HA-specific antibodies to SCID mice can protect them for an influenza
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infection (161, 162). These experiments clearly suggest the significant contributions of B
cells and anti-viral antibodies in recovery from an influenza infection. Following
exposure to an influenza infection, two compartments of memory B cells develop. One
subset is comprised of long lived plasma cells or antibody secreting cells (ASC) that
localize in the bone marrow and continuously generate antibodies to maintain an
optimal level of plasma antibodies for protection against re-infection. The other
compartment is populated with quiescent memory B cells that localize in lymphoid
tissues or lungs and require stimulation by a recall antigen to divide and differentiate
into ASCs (163).
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6. Research objectives
In the past decades, DCs have been the subject of extensive research because of
their versatile role in organizing the immune system both in health and illness. An array
of both endogenous (interferon, interleukin) and exogenous (bacterial, viral pathogens)
agents have been investigated for their role in the induction or inhibition of DC
maturation (164, 165). However, little is known about what dictates the differentiation
of DCs from bone marrow progenitor cells or monocytes. It is plausible to presume that
the local cytokine milieu plays a critical role in this process. In vitro, GM-CSF and IL-4 are
widely used to facilitate generation of DCs from monocytes, whereas other cytokines
e.g. IL-10 and IL-6 can block this differentiation pathway (166-169). Knowledge about
the effects of microbial infections on this differentiation process is still limited.
Recently, a body of accumulating evidence suggests that during infection or
inflammation, DCs differentiate more readily from monocytes than from bone marrow
precursor cells (170, 171). Preferential production of monocyte chemo-attractant
proteins over neutrophil chemo-attractant proteins has also been reported during
influenza infection (172). The number of monocytes that migrate to the respiratory
mucosa overwhelmingly exceeds the number of DCs (173). These findings underscore
the importance of monocytes in the replenishment of APCs in airway mucosa during
influenza infection. Therefore, it was hypothesized that virus-mediated impairment of
monocyte differentiation into DC may contribute to influenza virus pathogenesis and
also to evasion of host immune responses. Equine influenza viruses were used in an
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equine monocyte model to determine the effects of the viral infection upon the
differentiation of monocyte-derived DCs.
To test the experimental hypothesis, three specific aims were investigated: 1.
Determination of the ability of equine influenza viruses to infect and replicate in equine
monocytes when cultured in the presence of both eq.GM-CSF and eq.IL-4 for
differentiation into DCs. 2. Characterization of morphologic, phenotypic and functional
alterations of equine influenza virus infected monocytes with respect to their capability
to differentiate into DCs. 3. Determination of the role of virus subtype and influenza NS1
protein in the virus mediated inhibition.
The experimental approaches that were used for evaluating aforementioned
specific aims are as follows. In specific aim 1, the ability of equine influenza virus to
replicate in equine monocytes was investigated by assessing the transcription of viral
genomic RNA in infected monocytes and also by measuring viral protein (NP) synthesis
and progeny virus production. Cytotoxicity of the virus was determined by its ability to
induce apoptosis in infected cells. For specific aim 2, influenza virus infected monocytes
were first evaluated microscopically for their morphologies and then analyzed by flow
cytometry for phenotypic expression of DC surface markers. Functional inhibition due to
the viral infection was measured by the endocytic ability and cytokine production by
infected monocytes. Finally, the role of virus subtype and influenza NS1 protein in this
process was examined in specific aim 3 by employing an H3N8 virus and another NS1truncated virus.
Copyright © Saikat Boliar 2009
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CHAPTER II
MATERIALS AND METHODS

Purification of equine monocytes from PBMC
Isolation of equine monocytes from peripheral blood mononuclear cells (PBMC)
and further culture for differentiation into DCs was carried out according to a previously
published method (129). Horses were randomly selected from a population maintained
at the University of Kentucky Maine Chance Farm and screened for presence of serum
antibody against a panel of equine influenza viruses. A group of influenza sero-negative
horses (n = 10, of mixed breed, age and sex) were finally selected for all future
experiments. Briefly, blood was collected in heparin containing tubes or bottles and was
placed at room temperature for 30 min for clear separation of plasma from red blood
cells. PBMCs were isolated from this heparinized blood by Ficoll-Paque density gradient
centrifugation. Blood plasma including the Buffy coat was carefully layered onto 10 ml
of Histopaque – 1077 (Sigma Aldrich) in 50 ml conical tubes (Corning) and was
centrifuged at room temperature (22°C) at 400g for 30 min without brakes (Beckman
GS-6KR centrifuge, rotor type GH-3.7). A creamy white band of PBMCs that appeared at
the interface between the plasma and Histopaque – 1077 was collected and washed
twice with PBS (BioWhittaker, pH 7.4) by centrifugation at 500g for 5 min. PBMCs were
then suspended in complete RPMI medium (cRPMI; RPMI-1640 containing 10%
autologous horse serum, 2mM L-glutamine, 55μM ß–mercaptoethanol, 100 U/ml
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penicillin-streptomycin and 0.25μg/ml amphotericin B) at a density of 107 cells per ml
and plated in 100 mm tissue culture treated plates. For the autologous serum used in
cRPMI medium, blood was collected in 10 ml tubes (BD vacutainer™), incubated at 37°C
for 30 min and then centrifuged at 900g for 10 min. After 4 hrs of incubation at 37°C
with 5% CO2, non-adherent cells (mainly lymphocytes) were removed by gently washing
the plates twice with warm PBS. In a few occasion, adherent cells were stained for CD14
(Big 10, Axxora Platform) and examined by flow cytometry (FACScan, Becton Dickinson)
to determine the purity of monocytes among adherent cells.
To stimulate differentiation into DCs, purified monocytes were further cultured
in cRPMI medium supplemented with eq.GM-CSF and eq.IL-4 (CHO cell supernatants
containing recombinant eq.GM-CSF and eq.IL-4 were added at 10% each) at 37°C with
5% CO2 for 4 days.

Preparation of virus stock
Equine influenza viruses that were used for different experiments are: (1)
Influenza

A/equine/New

York/49/73,

(H7N7

subtype);

(2)

Influenza

A/equine/Kentucky/5/02, (H3N8 subtype) and (3) Influenza A/equine/Kentucky/5/02
NS1-73, a carboxy-terminally truncated virus (a kind gift from Dr. Peter Palese, Mount
Sinai School of Medicine). The Kentucky/5/02 NS1-73 is a recombinant H3N8 subtype
virus that expresses only the N-terminal 73 amino acid residues out of the full 219
amino acid long NS1 protein (174). Wild type viruses (NY/73 and KY/02, virus repository,
OIE equine influenza reference laboratory, University of Kentucky) were propagated in

38

pathogen free 10-day-old embryonated chicken eggs whereas immune-incompetent 7day-old eggs were used for the recombinant virus (KY/02 NS1-73) since this virus lacks
proper anti-interferon activity. Viruses (0.1 ml per egg, 1:1000 dilutions in PBS) were
inoculated into allantoic cavities and then incubated at 37°C for 72 hrs. Allantoic fluids
were harvested and then clarified of any egg debris by centrifugation. Titration of the
stock virus was done by 50% egg infectious dose (EID50) assay as described by Reed and
Muench (175). Stock virus was stored in 1 ml aliquots at – 80°C.
Where needed, viruses were inactivated by UV irradiation using a UV Stratalinker
1800 (Stratagene). Briefly, a thin layer of 1 ml virus was poured into a 35 mm plate,
placed on ice and irradiated at 254 nm for 30 min at a distance of 10 cm. Proper
inactivation was confirmed by inoculation of 0.1 ml of irradiated virus into a 10-day-old
embyronated chicken egg. Although UV irradiated viruses could not replicate, they
retained their receptor binding (cell attachment) capability as they could agglutinate
chicken RBCs in the hemagglutination (HA) assays.

Infection of equine monocytes with equine influenza virus
Before infection, monocytes were washed twice with PBS to remove serum. The
virus stock was diluted in serum free infection medium (cRPMI with 0.25 % bovine
serum albumin replacing 10 % autologous horse serum plus 1μg/ml TPCK trypsin).
Monocytes were infected with an infectious dose of approximately 5 EID50 units per cell
or an equivalent amount of UV inactivated virus. Mock inoculums consisted of only the
infection medium. After 1 hr of adsorption at 37°C, viral inoculums were removed; cells
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were washed twice with PBS and then cultured in cRPMI medium with 1μg/ml TPCKtrypsin for 4 days or as otherwise mentioned.

Quantification of viral RNA levels in infected cells
To determine whether equine monocytes cultured in the presence of eq.GM-CSF
and eq.IL-4 can support replication of equine influenza virus, viral genome transcription
in infected cells was measured by relative real-time PCR assay. Purified equine
monocytes were plated at 106 cells per ml and incubated overnight in cRPMI
supplemented with eq.GM-CSF and eq.IL-4. The next day, cells were infected with
equine influenza virus as described earlier. Following infection, cell samples were
collected at different time points post-infection (p.i.) e.g. 0, 4, 8, 12 and 24 hrs. Total
cellular RNA was extracted from collected samples using the RNeasy Mini Kit (Qiagen)
following manufacturer’s instructions. Possible DNA contamination was eliminated by
in-column treatment with DNase I (RNase free DNase set, Qiagen). Taqman® one-step
RT-PCR master mix reagents (Applied Biosystems) and an ABI Prism 7500 fast real-time
PCR system (Applied Biosystems) were used to perform the assay. Five micrograms of
extracted RNA were added to a total reaction volume of 20μl in a 96 well plate (Applied
Biosystems). Primers and probe (TaqMan MGB), used in this experiment, were designed
to amplify a 63bp region of the NP gene. The program for amplification consisted of a 30
min period at 48°C, then 10 min at 95°C followed by 40 cycles with the following
conditions: 95°C for 15 sec and 60°C for 1 min. Threshold cycle (Ct) values of respective
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samples were normalized by comparison with the ribosomal protein large PO (RPLPO)
RNA level.
EqFlu NP forward primer:

5’- GAAGGGCGGCTGATTCAGA -3’

EqFlu NP reverse primer:

5’- TTCGTCGAATGCCGAAAGTAC -3’

EqFlu NP probe:

5’- CAGCATAACAATAGAAAGGA -3’

Quantification of viral protein synthesis in infected cells
Viral protein synthesis in infected monocytes was quantified by detecting NP
protein levels using flow cytometry. Following infection of monocytes, samples were
collected at 5 different time points p.i. (0, 4, 8, 12 and 24hrs). Cells were washed twice
with PBS and then fixed with 2% paraformaldehyde in PBS for 1 hr at room temperatute.
Cellular permeabilization was achieved by incubating samples in 0.5% saponin, 5% FBS
in PBS solution for 15 min at 4°C. After washing twice with PBS, cells were first stained
with the primary antibody (Mouse influenza A anti-NP, clone # M2110169, Fitzgerald
Industries International Inc.) and then with a FITC-conjugated secondary antibody
(Immunopure goat anti-mouse IgG, F(ab’)2, Pierce) at 37°C for 30 min each (1 μg of Ab
per 106 cells). Subsequently, all samples were washed twice, resuspended in 400μl FACS
buffer (PBS with 1% BSA and 0.1% sodium azide) and analyzed with by flow cytomerty
(FACScan, Becton Dickinson) for their respective mean fluorescence intensities (MFI).
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Detection of apoptosis in virus infected monocytes
Influenza virus infected or mock inoculated monocytes were further cultured in
cRPMI medium with eq.GM-CSF and eq.IL-4 for 4 days. On day 4 p.i., cells were
collected, washed in PBS and then resuspended in Annexin V binding buffer at the rate
of 106 per ml. Next, 105 cells were used for staining with Annexin V and propidium
iodide (PI) according to manufacturer’s instructions (Annexin V-FITC apoptosis detection
kit I, BD Pharmingen). After 15 min of incubation at room temperature, cells were
analyzed by flow cytometry. When cells start to undergo apoptosis, phosphatidylserine
(PS), a membrane phosphor lipid, translocates from inside to the outer side of the
membrane. Annexin V then binds to PS on apoptotic cells in a calcium dependent
manner. PI is used to separate viable cells from the non-viable ones.

Analysis of cell count, viability and average diameter
Vi-Cell

TM

(Beckman Coulter), an automated cell viability analyzer, was used to

determine total cell counts, percent of viable cells and their average diameters. Briefly,
cells were diluted in PBS at 1:10 ratio and then were run through the analyzer using the
program specific for PBMC. This automated machine uses trypan blue exclusion method
and video imaging to determine cell viability as well as the average diameter of the cells.

Analysis of cell surface marker expression by flow cytometry
Levels of expression of different cell surface markers for DC on mock- or
influenza infected cells were examined by flow cytometry (176). On day 4 p.i., cells were
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collected, washed twice with PBS and then resuspended in FACS buffer (PBS
supplemented with 1.0% BSA and 0.1% sodium azide). Pre-incubation with purified
horse IgG (ChromPure horse IgG, Jackson ImmunoResearch) for 30 min was used to
block non-specific binding through Fc receptors. Cells were then incubated with either
primary or fluorochrome-conjugated antibodies (1 μg of Ab per 106 cells) for 30 min at
4°C. The following antibodies were used: CD172a (DH59B, VMRD), CD1w2 (MCA2058PE,
AbD Serotec), CD86 (IT2.2, Biolegend), MHCI (CVS22) and MHCII (CVS10, both CVS mAbs
were gifts from Dr. Paul Lunn, University of Colorado). After labeling with primary
antibodies, cells were washed twice with FACS buffer and then stained with FITC labeled
secondary antibodies for 15 min at 4°C. Isotype-matched antibodies (BD Pharmingen)
were used as negative controls. Cells were fixed with 2% paraformaldehyde in FACS
buffer and then analyzed via flow cytometry (FACScan, Becton Dickinson). Cells were
gated based on forward- and side-scatter profile and data were analyzed using
CellQuest TM software.

Quantification of cellular gene expression by real-time PCR
Cellular gene expression levels were quantified by two-step real-time PCR assays
(RT-PCR). Total cellular RNA was extracted from infected cells with RNeasy Mini kit
(Qiagen) as described earlier in this chapter. Then, following manufacturer’s
instructions, 1μg of the extracted RNA was reverse-transcribed into cDNA using
Stratascript cDNA synthesis kit (Stratagene). Oligo-dT primers were used in the assay to
selectively amplify cellular mRNAs. Gene-specific, intron-spanning primers and probes
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used in these assays are listed below (Table 2.1). TaqMan® Fast Universal PCR master
mix (Applied Biosystems) was added in 10μl of reaction mixtures in a 96 well plate and
the fast amplification cycle (20 sec at 95°C, followed by 40 cycles of 3 sec at 95°C and 30
sec at 60°C) of an ABI Prism 7500 fast real-time PCR system was used to perform the
experiments. Initially several house-keeping genes (RPLPO, ß-GUS, GAPDH, ß-2microglobulin, phosphoglycerate kinas 1 and ß-actin) were tested and the expression
level of RPLPO was found to be the most stable during influenza virus infection of
monocytes. Therefore, RPLPO was applied to normalize the data. The relative
expression levels of different genes were determined (2-∆∆CT) by using the method of
Livak and Schmittgen (177).
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Table 2.1: Primers and probes for two-step RT-PCR assay.
Target

Sequences (5’-3’)

References

gene

RPLPO

Fwd: CTGATTACACCTTCCCACTTGCT
Rev: AGCCACAAATGCAGATGGATCA
Probe: FAM-AAGGCCTTGACCTTTTC-NFQ

CD11c

Fwd: CTGATTTCCTGACCCACCTTCA
Rev: ACCTCAGGCAGTCAGCAATG
Probe: FAM-CTGTGCTGGACTGCTC-NFQ

CCR5

Fwd: GCAGAGCAGCTGAGACATCT
Rev: GGACTTGTCGTCTGATAATCCATCT
Probe: FAM-CAACCCAGGAGGCCTT-NFQ

(176)

CCR7

Fwd: GTGGTGGCTCTCCTTGTCA
Rev: AATCGTCCGTGACCTCATCTTG
Probe: FAM-CAGGCACACCTGGAAAA-NFQ

(176)

IL-10

Fwd: AGGACCAGCTGGACAACATG
Rev: GGTAAAACTGGATCATCTCCGACAA
Probe: FAM-CCAGGTAACCCTTAAAGTC-NFQ

(176)

IL-12

Fwd: CTACACCAGCGGCTTCTTCAT
Rev: GCTTCAGCTGCAGGTTCTTG
Probe: FAM-CAGGGACATCATCAAACC-NFQ

(178)

TGF-ß

Fwd: CCCTGCCCCTACATTTGGA
Rev: TGTACAGGGCCAGGACCTT
Probe: FAM-CCTGGACACGCAGTACAG-NFQ

(176)

IFN-α

Fwd: GCTGCTCTCTGGGATGTGA
Rev: TTTGTCCCAGGAGCATCAAGAC
Probe: FAM-CCTGCCTCACACCCATAG-NFQ

(178)

TNF-α

Fwd: TTACCGAATGCCTTCCAGTCAAT
Rev: GGGCTACAGGCTTGTCACTT
Probe: FAM-CCAGACACTCAGATCAT-NFQ

(178)
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Alpha-naphthyl acetate esterase (ANAE) assay
Mock or virus infected cells were collected at 4 days p.i., washed twice with PBS
and then smeared onto an 8-well slide. The slide was air-dried, fixed and then analyzed
for ANAE activity using alpha-naphthyl acetate (Sigma Aldrich) as the substrate as per
the manufacturer’s instructions and in accordance of previously published methods
(179). Presence of ANAE was determined microscopically by the appearance of dark,
black granulations at the site of enzymatic activity.

DQ-ovalbumin (DQ-OVA) endocytosis assay
DQ-ovalbumin (DQ-OVA, Molecular Probes) is a pH insensitive BODIPYconjugated self-quenching dye which emanates fluorescence (505-515nm) upon
protease degradation following endocytosis. On day 4 p.i., cells were collected, washed
twice in PBS and then resuspended at 5 x 105 per ml in cRPMI medium. DQ-OVA (10μl,
1mg/ml) was added to 100μl of cell suspensions and incubated at 37°C or 4°C (negative
control). After 1 hr of incubation, cells were washed thrice with ice-cold cRPMI media
containing 10% autologous horse serum to remove unbound or non-specifically bound
antigens. Cell samples were then resuspended in FACS buffer and evaluated by flow
cytometry. The endocytic capacity of mock or virus infected cells was determined by the
differences in mean fluorescence intensities between the treated and control samples.
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Statistical analysis
Data were analyzed by the one-way analysis of variance (ANOVA) and the
Tukey’s multiple comparison tests using the GraphPad Prism 5 statistical software
(GraphPad Software Inc.). A p value of less than 0.05 (95% confidence level) was
considered to be significant.

Copyright © Saikat Boliar 2009
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CHAPTER III
RESULTS

The hypothesis of whether influenza virus infection hinders monocyte
differentiation into DC was tested by evaluating the following results. In specific aim 1,
transcription of viral genomic RNA and subsequent viral protein synthesis and progeny
virus production in infected monocytes was quantified to assess whether equine
influenza virus can replicate in equine monocytes cultured with both GM-CSF and IL-4.
The ability to induce apoptosis in infected cells indicated viral cytotoxicity. In specific
aim 2, microscopical examination for morphologies and analysis by flow cytometry for
phenotypic expression of DC surface markers was done to evaluate the ability of
influenza virus infected monocytes to differentiate into DCs. Functional inhibition due to
the viral infection was measured by the endocytic ability and cytokine production by
infected monocytes. Finally, an H3N8 virus (KY/02) and another NS1-truncated virus was
used in specific aim 3 to evaluate if the viral inhibition is dependent on virus subtype
and the NS1 protein function.
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Proportion of monocytes in adherent cell population
Following isolation of PBMC, plastic adherent cells were analyzed by flow
cytometry to evaluate the percenta
percentage
ge of monocytes within the cell population. CD14
was used as the marker
arker for monocytes and about 73.6
73.6%
% of the cells were found to be
expressing CD14 on their cell surface. Therefore, this adherent cell population was used
as the source of monocytes for furt
further experiments.

Figure 3.1: Percentage of monocytes in adherent cells. Adherent PBMCs were stained
with monoclonal anti-CD14
CD14 antibody (Big 10, Axxora Platform
Platform) and
nd then analyzed by
flow cytometry. Empty black line represents the isotype control.
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Influenza virus infection of monocytes
Monocytes,, after overnight pre
pre-treatment with GM-CSF and IL-4
4 in culture, were
infected with influenza virus (NY/73, H7N7) at an infectious dose of 5 EID50 units per cell.
To evaluate successful infection of monocyte
monocytess with influenza virus, cells were evaluated
eval
for expression of viral nucleo
nucleoprotein (NP) 24 hr p.i. About 59% (59.15 ± 2.87, N=5) of the
adherent cells were found to express NP protein.

Figure 3.2: Percentage
entage of cells positive for viral NP. Monocytes infected with NY/73
virus were cultured with GM
GM-CSF and IL-4
4 for 24 hr and then stained intracellularly with
mouse anti-influenza
influenza NP antibody. Empty black line shows the control of uninfected
cells stained with anti-NP
NP antibody
antibody. Figure is representative of 3 separate experiments.
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Influenza viral RNA transcription in monocytes cultured with GM-CSF and IL-4
The ability of equine influenza virus (NY/73, H7N7 subtype) to replicate in
actively differentiating monocytes was first evaluated by examining viral genome
transcription. Before infecting with the virus, monocytes were pre-incubated overnight
with GM-CSF and IL-4 to initiate the differentiation process. Upon entering into cells,
viral genome transcription was evaluated by quantifying influenza virus nucleoprotein
(NP) RNA levels at various time points post-infection (0, 4, 8, 12 and 24 hr p.i.).
Monocytes in culture for DC differentiation allowed initiation of influenza genome
transcription as viral NP RNA level continued to increase until 12 hr p.i. when it reached
about 12-fold the amount of initial infectious viral RNA (Figure 3.3). However, after 12
hr p.i., viral RNA level started to decline. On the other hand, in UV-inactivated influenza
infected cells, no significant increase in NP RNA level was observed which further
confirmed successful inactivation of the virus through UV irradiation. However,
detection of NP RNAs in UV-inactivated influenza infected cells showed that those
viruses retained their cellular attachment and entry capabilities.

51

NP RNA level
14
Fold increase

12
10
8

N=3

6

NY73 live

4

NY73 inactive

2
0
0 hr

4 hr

8 hr

12 hr

24 hr

Figure 3.3: Viral genome transcription in influenza infected monocytes. Nucleoprotein
(NP) RNA levels in UV-inactivated and live virus (NY/73) infected monocytes were
measured by RT-PCR assays and were normalized based on RPLPO RNA levels. Results
are expressed as fold-increase (mean ± SD) over 0 hr p.i.
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Influenza viral protein synthesis in monocytes cultured with GM-CSF and IL-4
Since equine influenza virus (NY/73, H7N7) was able to transcribe its RNA
genome in infected monocytes, we next evaluated whether it could translate its viral
proteins. When virus infected monocytes were analyzed by flow cytometry for NP
protein levels, an early restriction in viral protein synthesis was observed (Figure 3.4).
Following infection, the virus started to synthesize viral NP protein which was evident by
the sharp increase in mean fluorescence intensity (MFI) at 4 hr p.i. However, after this
time point, NP protein level decreased continuously. At 24 hr p.i., fluorescence for NP
protein was almost half that of at 4 hr p.i. This showed that monocytes stimulated for
DC differentiation imposed an early inhibition in viral protein synthesis.
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Viral NP Protein Synthesis

MFI

NP protein level
400
350
300
250
200
150
100
50
0

N=3
NY73 live

Mock 0 hr

4 hr

8 hr

12 hr 24 hr

Figure 3.4:: Viral protein synthesis in influenza infected monocytes. Monocytes were
pre-treated
treated overnight with GM
GM-CSF and IL-4 before infection.
n. Synthesis of viral
nucleoprotein
ein (NP) in live virus (NY/73) infected monocytes were detected by flow
cytometry with mouse anti-influenza NP antibody. Results aree expressed as mean
fluorescence intensity (MFI) ± SD.
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Progeny virus production in monocytes cultured with GM-CSF and IL-4
Ability of GM-CSF and IL-4 pre-treated monocytes to support influenza virus
replication was further evaluated by quantification of progeny virus production by
infected cells. Cell supernatants were collected from infected monocytes (2 X106 cells,
MOI of 5 EID50 units per cell) at 0 and 24 hr p.i. and presence of live virus particles was
measured by 50% egg infectious dose assay. Loose attachment of monocytes to the
plate prevented vigorous washing of cell surface after infection which resulted in
substantial titer at 0 hr p.i. However, when viral titer at 24 hr p.i. was compared to that
of 0 hr, only 10-fold increase in EID50 titer was observed (Table 3.1). This is significantly
less than what is normally observed with more permissible cells such as MDCK (2 X 106
cells, MOI of 5 EID50 units per cell; Table 3.1). This demonstrated that GM-CSF and IL-4
treated monocytes were non-permissive to influenza virus as only limited progeny virus
production was achieved.

Table 3.1: EID50 titers of influenza virus infected monocytes and MDCK cells.
EID50 titer

0 hr p.i.

24 hr p.i.

Fold difference

Monocytes

9.8 X 104

10.5 X 105

10.7

2.81 X 105

6.58 X 107

234.1

(GM-CSF & IL-4)
MDCK cells
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Level of apoptosis of developing DCs following influenza infection
Having established that influenza virus infection of differentiating monocytes is
abortive or minimally-productive, we next investigated whether this limited virus
replication could inflict any toxic effect i.e. apoptosis in differentiating monocytes.
Mock- or virus-infected monocytes were cultured for 4 days in cRPMI supplemented
with GM-CSF and IL-4. Annexin-V (apoptosis) and propidium iodide (loss of cell
membrane integrity) staining of cells revealed that the presence of GM-CSF and IL-4 in
the culture media of mock-infected monocytes did not adversely affect their viability
(86.7% vs 84.0%, data not shown). When influenza virus-infected monocytes were
cultured with GM-CSF and IL-4 for 4 days, the level of apoptosis was significantly higher
than in mock infected cells (10.3% vs. 1.8%, p <0.01, Figure 3.5). However, considering
the fact that an infectious dose of 5 EID50 units per cell succeeded at inducing apoptosis
in only about 10.3% of the cells and the majority of cells (about 76.9%) were still viable
based on trypan blue staining at 4 days p.i., it can be concluded that influenza virus
infection did not induce substantial toxicity or apoptosis in developing DCs.
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PI

Mock

NY73 infected
Annexin V

Figure 3.5: Apoptosis of influenza virus infected monocytes cultured in GM-CSF
GM
and
IL-4. Mock or NY/73 influenza virus infected (MOI = 5 EID50 units/cell) monocytes at 4
days p.i. were stained with FITC
FITC-conjugated
conjugated annexin V and propidium iodide (PI) and
analyzed by flow cytometry. Percents of cells in four quadran
quadrants
ts of the dot plots are
shown as mean ± SD from 4 separate experiments
experiments.
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Morphology of mock and influenza virus (NY/73) infected monocytes
The morphological distinction between mock- or influenza-infected monocytes
was determined by inverted light microscopy (Figure 3.6). After 4 days of incubation,
mock-infected monocytes showed typical DC-like appearances such as finger-like
projections. Fully differentiated DCs were observed as loose floating clumps of large,
viable cells. On the other hand, infected cells failed to acquire DC-like processes and
many cells were found to float as a single cell or dense clumps of dark cells. Monocytes
infected with UV inactivated virus exhibited DC morphology, although the proportion of
DC-like cells was smaller than in the mock infected population (Figure 3.6). The average
diameter, as obtained by Vi-Cell

TM

cell viability counter (Beckman Coulter), also

indicated that influenza-infected monocytes did not increase significantly in size as
compared to their mock-infected counterparts (Figure 3.7). Differences between live
influenza infected monocytes and both mock and UV-inactivated virus infected cells
were also significant (Figure 3.7). Analysis by flow cytometry, as well, revealed a lower
degree of granularity for the virus-infected cell populations as most of the virus infected
cells, similar to monocytes, were still congregated in the lower right quadrant of the dot
plot.
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10X

100X

Mock

NY73 inactivated

NY73 live

Figure 3.6: Light microscopy images (10X and 100X magnifications). Mock, UVinactivated and live influenza virus (NY/73) infected monocytes were cultured in cRPMI
media supplemented with GM-CSF and IL-4 for 4 days and observed for DC morphology
under a light microscope.
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Avr. Diam. ((μm ± SD)

Monocyte

9.02 ± 0.20*,†

Mock

9.99 ± 0.17*,a

NY73

9.88 ± 0.21†,b

Dot Plot

inactivated

NY73 live

9.02 ± 0.45a,b

Figure 3.7:: Average diameter and dot
dot-plot analysis. Average diameters (mean
(
± SD,
N=4) of monocytes, mock, UV
UV-inactivated and influenza virus (NY/73) infected
monocytes were measured with a Beckman Coulter ViCell TM cell viability counter. A
confidence interval of 95% was used to determine significant increases in diameters (*,
†, a, b = p <0.05). The lower panel shows flow cytometry dot plots (forward vs. side
scatter). Cells with increased granularity tend to move towards upper right quadrant.
Numbers in the figures indicate percents of cells within that quadrant.
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Expression of DC surface molecules on influenza virus (NY/73) infected monocytes
Successful differentiation of monocytes into DCs was confirmed by analysis of a
set of distinctive surface molecules. Monocytes were infected with 5 EID50 units per cell
of live influenza virus or equivalent amount of UV-inactivated virus; cultured in presence
of GM-CSF, IL-4 for 4 days and then compared with their mock-infected counterparts for
relevant phenotypes. Differentiated DCs are characterized by high levels of CD11c,
CD1b, CD86, MHC I and MHC II. Accordingly, mock-infected monocytes which effectively
differentiated into DCs, up-regulated CD11c gene expression by almost 20-fold (p <0.05)
compared to non-stimulated monocytes (Figure 3.8). In contrast, CD11c expression on
live influenza infected monocytes was nearly negligible (p<0.05 vs mock) and UVinactivated virus treated monocytes exhibited only moderately (5-fold) increased CD11c
gene expression (Figure 3.8). Similarly, CD172a (a myeloid marker) was found on 86% of
mock–infected monocytes whereas only 66.1% and 36.2% of UV-inactivated or live virus
treated cells were positive for this marker respectively (Figure 3.9). This expression level
of CD172a on live virus infected monocytes was significantly lower (p <0.05) than the
mock cell population. Mock-infected cells also had a significantly higher (p <0.05)
number of CD1w2 (human CD1b homolog) positive cells than either of the virus infected
cell populations (Figure 3.10). Influenza virus infected monocytes also failed to upregulate expression of “immature” DC-associated chemokine receptor, CCR5 as
efficiently as mock or UV-inactive virus treated cells (Figure 3.8). On the other hand,
expression of CCR7, which is predominantly found at high levels on “mature” DCs, did
not vary significantly among mock and virus treated cell populations (Figure 3.8).
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However, percentage of cells expressing CD86, MHC I and MHC II were comparable
among mock, UV-inactivated or live influenza virus infected cells (Figure 3.11). On the
other hand, when the mean fluorescence intensities (MFI) were evaluated, these were
considerably higher for both UV-inactivated and live virus infected cells as compared to
mock samples (Figure 3.12). These results indicated that influenza virus infection of
monocytes impeded expression of different surface antigens characteristic of DC
differentiation. Since the phenotype of UV-inactivated virus treated monocytes, as
evaluated from the surface antigen expression profile, lay intermediate between mockand live influenza virus infected cells, it appears that at least limited viral replication was
necessary for significant inhibition of monocyte differentiation into DCs.
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Figure 3.8: Gene expression of CD11c, CCR5 and CCR7. Relative RT-PCR was used to
measure gene expression levels. Data were normalized based on house-keeping gene,
RPLPO and shown as mean ± SD. A p value of 0.05 or less was considered significant.
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Figure 3.9: Surface expression of CD172a. Mock, UV-inactivated
(NY/73) infected monocytes were stained with anti
anti-CD172a
CD172a antibody (DH59B) at day 4
p.i. and analyzed by flow cytometry. Percentage of CD172a positive cells are shown as
mean ± SD (N=4; *= p <0.05
<0.05).
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Figure 3.10: Surface expression of CD1w2. Mock, UV-inactivated
inactivated and live influenza virus
(NY/73) infected monocyt
monocytes were stained with anti-CD1w2
CD1w2 antibody (MCA2058PE)
(MCA2058PE at
day 4 p.i. and analyzed by flow cytometry. Percentage of CD1w2 positive cells are shown
as mean ± SD (N=4; *, †= p <0.05
<0.05).
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CD86, MHC I and MHC II surface expressions on mock, UVFigure 3.11: Histograms of CD
inactivated and live influenza virus (NY/73) infected monocytes. Empty black lines
represent isotype matched controls. Mean percentage of positive cells from 4 separate
experiments are labeled on the plots.
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Figure 3.12: Mean fluorescence intensity (MFI) of CD86, MHC I and MHC II surface
expressions. Data are shown as mean ± SD (N=4). A p value of less than 0.05 was
considered significant.
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Alpha-naphthyl acetate esterase (ANAE) activity of influenza virus (NY/73) infected
monocytes
Dendritic cell differentiation from monocytes was further investigated by
cytochemical staining for ANAE. This is a family of non-specific esterase enzymes which
is found uniformly throughout the cytoplasm of monocytes and macrophages (180,
181). Mock infected monocytes which successfully differentiated into DCs, had very
faint and focal ANAE staining mainly around the nucleus (Figure 3.13). Influenza virus
infected cells retained considerable enzymatic activity as observed by the dense and
diffuse ANAE staining throughout the cytoplasm. The staining for UV inactivated virus
treated cells fell intermediate between mock- and live virus infected cells.
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Figure 3.13: ANAE activity in influenza infected monocytes. Mock, UV-inactivated and
live influenza virus (NY/73) infected monocytes were cultured in presence of GM-CSF
and IL-4 for 4 days and then stained for non-specific esterase. Dark black granulations
are indicative of ANEA activity.
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Endocytosis by influenza virus (NY/73) infected monocytes
The ability of influenza infected monocytes to acquire DC-like functions was
evaluated by determining their antigen endocytosis capability. Mean fluorescence
intensity of DQ-ovalbumin which liberates fluorescence upon endocytosis was used as
an indication of antigen uptake ability. As shown in Figure 3.14, mock infected cells had
significantly higher (p<0.05) endocytic function (high MFI), while live virus infected ones
failed (low MFI) to uptake DQ-OVA through receptor mediated endocytosis. Consistent
with other results, UV-inactivated virus treated monocytes showed a partially reduced
endocytic activity compared to mock cells although significantly more than live influenza
infected monocytes. These data suggest that live influenza virus infection successfully
prevented monocytes from acquiring endocytic function.
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mediated endocytosis of DQ
DQ-ovalbumin. Mock, UV-inactivated
UV
Figure 3.14: Receptor-mediated
and live influenza virus (NY/73, H7N7) infected monocytes at 4 days p.i. were incubated
with DQ-ovalbumin
ovalbumin for 1 h at 4°C (black line) or 37°C (green). Level of antigen
endocytosis was analyzed by flow cytometry and measured by the mean fluorescence
intensity (MFI). Numbers in the figures indicate averag
averagee MFI of 4 separate experiments.
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Cytokine production by influenza virus (NY/73) infected monocytes
Since cytokines play a critical role in monocyte differentiation into DCs,
production of IL-10, IL-12 and TGF-ß which are known to influence DC development was
analyzed. Mock or influenza virus infected cells were analyzed for their intracellular
cytokine mRNA synthesis. Mock infected cells had considerably higher IL-12 mRNA level
than live influenza virus infected monocytes (Figure 3.15). On the other hand, virus
infection enhanced IL-10 mRNA transcription by 3-fold over mock infected cells (Figure
3.15). Another cytokine, TGF-ß which favors DC differentiation was also significantly
down-regulated in influenza virus infected monocytes (Figure 3.15, p <0.05). These data
indicated that IL-12, a pro-inflammatory cytokine produced by DCs, was down-regulated
in influenza virus infected monocytes whereas IL-10, a reciprocal regulatory cytokine to
IL-12, was up-regulated which would be favorable for arresting monocyte differentiation
into DCs.
Other inflammatory cytokines, however, were differently influenced by the viral
infection. Live influenza virus infection significantly up-regulated gene expression of IFNα and TNF-α as compared to mock infected monocytes (Figure 3.15, p <0.05).

72

IL-12
Rel. Expression

3
2.5

N=4

2
1.5
1
0.5
0
Mock

NY73inactive

NY73live

IL-10
Rel. Expression

12

*, †

10

N=5
*, † = p < 0.05

8
6

†

4
2

*

0
Mock

NY73inactive

NY73live

Rel. Expression

TGF-beta
1.4
1.2
1
0.8
0.6
0.4
0.2
0

N=4
* = p < 0.05

*

*

Mock

NY73inactive

73

NY73live

IFN-alpha
10

*

Rel. Expression

8
6

N=4
* = p <0.05

4
2

*

0
Mock

NY73inactive

NY73live

TNF-alpha
7

†

Rel. Expression

6
5
4

N =4
* = p <0.05

*

3
2

*, †

1
0
Mock

NY73inactive

NY73live

Figure 3.15: Cytokine production by influenza infected monocytes. Mock, UVinactivated or live influenza virus (NY/73) infected cells were cultured in GM-CSF and IL4 for 4 days and mRNA levels of IL-10, IL-12, TGF-ß, IFN-α and TNF-α were quantified by
real-time PCR. RPLPO mRNA levels were used to normalize the data. Results are shown
as mean ± SD. A p value of less than 0.05 was considered significant.
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Expression of DC surface molecules on monocytes infected with KY/02 and a NS1defective influenza virus
An H3N8 equine influenza virus (KY/02) and its NS1-truncated variant (KY/02
NS1-73) were utilized in order to investigate whether the viral inhibition is subtypedependent and if viral NS1 protein plays any role in the process. Similar to the
experiments with NY/73 virus, expression of DC markers such as CD11c and CD172a was
measured. The mock infected cells, as expected, enhanced their expression of CD11c
significantly (p <0.05) with respect to monocytes. But its expression on both wild type
and NS1-truncated virus infected monocytes was either comparable to or less than
monocytes and significantly lower than mock infected cells (Figure 3.16, p<0.05).
Similarly, fewer wild type virus (KY/02) infected monocytes expressed CD172a on their
surface than mock infected cells. The expression of this myeloid marker was even lower
in NS1-truncated virus infected monocytes (Figure 3.16). This demonstrated that both
H3N8 wild type and NS1-defective influenza viruses were able to hinder monocytes
from attaining distinctive DC phenotypes.
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Figure 3.16: Expression of DC surface on H3N8 influenza infected monocytes. Relative
RT-PCR was used to measure gene expression levels of CD11c. Expression levels were
normalized based on house-keeping gene, RPLPO. Surface expression of CD172a was
measured by flow cytometry. Data are shown as mean ± SD. A p value of 0.05 or less
was considered significant.
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Endocytosis by monocytes infected with KY/02 and a NS1-defective influenza virus
DCs are the most potent APCs and efficient endocytosis is a prerequisite for
presenting antigens on MHC molecules. When KY/02 wild type and the NS1-truncated
influenza virus infected monocytes were examined for their ability to uptake ovalbumin,
both wild type and NS1-truncated virus infected cells showed considerably less
endocytic function compared to mock infected monocytes (Figure 3.17). This indicated
that H3N8 influenza virus, similar to H7N7 subtype, was also able to inhibit antigen
uptake by monocytes and truncation of its NS1 viral protein did not hamper this
inhibition by the virus.
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Figure 3.17: Endocytosis of DQ-ovalbumin by H3N8 influenza infected monocytes.
Mock, KY/02 and NS1-truncated influenza virus (H3N8) infected monocytes at 4 days p.i.
were incubated with DQ-ovalbumin for 1 h at 4°C (black line) or 37°C (green). Level of
antigen endocytosis was analyzed by flow cytometry and measured by the mean
fluorescence intensity (MFI). Results are presented as mean ± SD.
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Cytokine production by monocytes infected with KY/02 and a NS1-defective influenza
virus
As described in chapter I (section 2.2.8), NS1 protein of influenza virus is a strong
antagonist of cellular interferon production. To evaluate whether truncation of NS1
protein affected this function, IFN-α productions by mock, wild type and NS1-defective
influenza virus infected monocytes were compared. Not surprisingly, NS1-truncated
influenza virus allowed infected monocytes to produce significantly more IFN-α (Figure
3.18).
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Figure 3.18: IFN-alpha production by H3N8 influenza infected monocytes. Relative RTPCR was used to measure gene expression levels. Data were normalized based on
house-keeping gene, RPLPO and shown as mean ± SD. A p value of 0.05 or less was
considered significant.
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CHAPTER IV
DISCUSSION

In spite of the extensive research done on influenza virus, our understanding of
the mechanism of its pathogenesis at the cellular level still remains incomplete. Because
of the segmented genome, it can undergo gene reassortment or antigenic shift which
can be indicted for the three documented human pandemics in the last century (5).
Again, its negative sense RNA genome requires viral RNA dependent RNA polymerase
for its replication whose error prone properties enable the virus to introduce point
mutations or antigenic drift which helps the virus in evading existing host antibodies.
While these strategies counteract the humoral immune response, influenza virus has
also evolved to escape the cell mediated immunity as well. For example, influenza virus
NS1 protein inhibits T cell activation and IFN-γ production (64). However, only limited
information is available on influenza virus mediated inhibition of the innate immunity.
DCs play a vital role in innate immunity as well as activation of adaptive immunity and as
mentioned in Chapter I, monocytes are a major source of these APCs, particularly during
infections. Therefore, in this dissertation, the effects of influenza virus infection on
monocyte differentiation into DCs were studied.
An equine virus-host model system has been utilized to evaluate the hypothesis.
Since influenza virus infections of mice do not always simulate natural infections, the
ability to examine the effects of equine influenza viruses on equine monocytes provides
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a distinctive opportunity of studying a virus in its natural host. The availability of large
amounts of blood from horses also satisfies the needs of the experiments, which could
otherwise pose a difficulty in human or mouse model systems. The discrete features of
two equine influenza subtypes (H7N7 and H3N8) also offered a prospect of investigating
whether viral subtype differences play any role in the process. It is noteworthy to
mention that equine-1 (H7N7) influenza viruses possess the basic amino acid containing
highly cleavable HA proteins which is a phenotypic attribute of pathogenic avian
influenza viruses. However, despite being highly virulent in mice, it only causes a mild
disease in horses (81). This offers the unique chance to investigate the effects of a
genotypically predicted highly virulent mammalian influenza virus on the differentiation
of monocytes into dendritic cells. A NS1-defective equine influenza virus was also
tested. As described in chapter I (section 2.2.8.), NS1 protein of influenza virus plays an
important role in viral pathogenesis and immune-evasion. The NS1-truncated virus that
was used in the experiments lacks the C-terminal “effector domain” which mediates
several of its anti-immune activities (section 2.2.8). So, contrasting the effects of wildtype and NS1-defective viruses on DC differentiation could illuminate additional roles of
this viral protein (NS1) in influenza virus pathogenesis.
During influenza virus infection, respiratory epithelial cells secrete an array of
inflammatory cytokines and chemokines that lead to a massive influx of immune cells
including monocytes into the airway mucosa. Microbial infections and allergens are
known to stimulate increased GM-CSF production by airway epithelial cells (182, 183),
that along with other cytokines can drive the priori uncommitted monocytes, now in the
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inflammatory milieu, to differentiate into either macrophages or DCs in order to supply
adequate APCs at the site of infection. Pre-treatment of cells with cytokines such as GMCSF have been found to modulate the outcome of viral infections. GM-CSF is a potent
cytokine which can stimulate cellular metabolism, RNA transcription and protein
synthesis as well as endocytosis (184). Accordingly, it has been shown that influenza
progeny virus production and cytotoxicity is increased when monocytes are cultured
with GM-CSF alone leading them towards the macrophage lineage (185). Similar results
are obtained when GM-CSF treated mononuclear phagocytes are infected with HIV (186,
187). IL-4, a Th2 type cytokine, also enhances replication of SIV when given to macaque
monkeys (188). Although the effects of GM-CSF and IL-4 on virus replication have been
demonstrated separately, the fate of virus infected monocytes cultured with both GMCSF and IL-4 and thus differentiating towards DCs, was yet unknown.
While monocytes in the blood stream are highly unlikely to become infected
with influenza virus, monocytes in the respiratory mucosa would come in contact with
an enormous number of virus particles produced by infected airway epithelial cells. So
in specific aim 1, the replication behavior of equine influenza virus in monocytes
cultured in the presence of both GM-CSF and IL-4 was characterized. Adherent cells
were used as the source of monocytes since about 73.6% of the population was
consisted of CD14 positive cells (Figure 3.1). An infectious dose of 5 EID50 units per cell
was chosen to ensure viral exposure to most of the cells. It was found that equine
influenza virus successfully infected monocytes, as about 59% of the adherent cells
expressed viral NP protein at 24 hr p.i. when analyzed by flow cytometry (Figure 3.2).
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Since It is known from a published report that influenza virus can not readily infect
lymphocytes, the reason for the other 41% of the cells not expressing viral NP protein
could be traced to the fact that about 73.6% of the adherent cell population was
monocytes (CD14 positive, Figure 3.1), while the rest would be comprised of primarily
lymphocytes, which are non-permissive to influenza infection (189). Successful
replication of the virus was also evaluated by its genome transcription ability, viral
protein synthesis and progeny virus production. As shown in Figure 3.3, the live virus
could transcribe its viral genome as opposed to the UV-inactivated virus. However, viral
protein synthesis ceased very early at 4 hr p.i. This resulted in a very limited progeny
virus production. The lack of cytotoxicity (Figure 3.5) of virus infected monocytes could
be associated with the inefficient viral protein synthesis. This is in stark contrast to the
infection of only GM-CSF pre-treated monocytes where influenza virus replicates
productively and induces much higher rate of apoptosis (185). Similar results are also
observed when equine monocytes are infected with equine influenza viruses (personal
communication, Liang Zhang). The reason for this inhibition due to GM-CSF and IL-4 pretreatment of monocytes is yet unclear. The most plausible explanation is that GM-CSF
and IL-4 pre-treatment sets off monocyte differentiation towards DCs and stimulates
production of cytokines (TNF-α, IFNs) which in turn can block influenza virus replication.
In fact, GM-CSF and IL-4 pre-treated monocytes, when infected with influenza virus,
expressed significantly higher levels of IFN-α and TNF-α than their mock infected
counterparts (Figure 3.15). Several reports have shown that IFNs induce expression of
anti-viral genes such as Mx and viperin which can inhibit influenza virus replication (145,
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190). While Mx inhibits viral mRNA synthesis, viperin interferes with the fluidity of
cellular lipid rafts and thereby prevents budding of progeny viruses from infected cells.
TNF-α also possesses a strong anti-influenza activity (191). Pre-treatment of otherwise
susceptible cells such as MDCK with TNF-α makes them resistant to viral cytopathic
effects by inhibiting viral protein synthesis. Additionally, the reduced level of apoptosis
in GM-CSF and IL-4 pre-treated monocytes could be due to the anti-apoptotic effects of
IL-4. It can activate signal transducer and activator of transcription 6 (Stat-6) and
phosphatidylinositol 3 kinase (PI3K) pathways which up-regulate anti-apoptotic protein
Bcl-xL and thereby prevent cells from undergoing apoptosis (192, 193). So these results
identify that influenza virus infection of blood monocytes culminate into two distinct
outcomes depending upon whether those cells are differentiating towards macrophages
or DCs.
Although influenza virus undergoes restricted replication in differentiating
monocytes, it was further investigated if the viral infection had any morphological or
functional effects on monocyte differentiation into DCs. When monocytes differentiate
into DCs, they acquire a distinctive DC-like morphology with veils and large finger-like
projections. In these experiments, mock and UV-inactivated virus infected monocytes
acquired the DC-like morphology, but live influenza virus infected monocytes remained
round and lacked dendritic processes (Figure 3.6). When cell diameter was measured,
equine monocytes had an average diameter of 8.92μm. Mock and UV-inactivated virus
infected monocytes, which successfully differentiated into DCs, had significantly
increased their average diameter to 10.00μm and 9.88μm, respectively. On the
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contrary, live virus infected monocytes failed to increase in size as their average
diameter (9.03μm) remained close to that of monocytes (Figure 3.7). Live virus infected
monocytes were also unsuccessful in increasing their cellular granularity as fewer cells
moved to the upper right quadrant of the dot plot compared to both mock and UVinactivated virus infected monocytes (Figure 3.7). Although the precise reason for the
inability of influenza infected monocytes to attain DC-morphology is unclear, viral
attachment and entry alone was not adequate to bring about the changes. Viral
genomic RNA transcription and limited viral protein synthesis was required for the
inhibition because UV-inactivated influenza infected monocytes successfully acquired
the DC-like morphology. These results showed that live influenza virus infected
monocytes failed to attain the morphological characteristics of DCs.
Apart from the morphological alterations, influenza virus infection of monocytes
also modified expression of different DC surface molecules. CD11c, an integrin, is a
specific marker for DCs and is expressed abundantly on myeloid and other types of DCs
(194). Thus, mock infected cells up-regulated expression of CD11c significantly (20-fold,
p< 0.05) over untreated monocytes (Figure 3.8). On the contrary, CD11c expression on
live virus infected monocytes was almost negligible. Similarly, live virus infected
monocytes failed to up-regulate expression of several other DC markers (CD172a,
CD1w2, CCR5; Figure 3.8 and 3.9). Interestingly, surface markers on monocytes infected
with UV-inactivated influenza virus, although considerably higher than live influenza
virus infected cells, were moderately lower than mock infected monocytes. The
expression of CD1w2 (human CD1b homolog), in particular, was remarkably low (Figure
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3.9). However, this finding corroborates with a previous report that TLR7/8 agonists
have an inhibitory effect on the surface expression of CD1 family members (195).
Although UV-inactivated influenza viruses could not replicate their viral genome, they
would retain enough genomic RNA to stimulate TLR7/8 in monocytes (Figure 3.3).
Considerably enhanced expression (MFI) of CD86, MHC I and MHC II on both UVinactivated and live influenza virus infected monocytes was also observed, which
suggests an involvement of TLRs which when activated are known to stimulate
expression of these co-stimulatory molecules (196). As suggested above, UV-inactivated
influenza virus, possibly through activation of PAMPs such as TLRs, was able to partially
modulate the phenotypic characteristics, but complete inhibition of appearance of DCspecific markers required at least limited viral replication as exemplified by live influenza
infected monocytes.
Effects of influenza virus infection on monocyte differentiation were further
characterized by cytochemical staining for ANAE. Splenic and tonsilar DCs are negative
for ANAE, but monocyte derived DCs retain a little enzymatic activity, although the
staining appears to be much more focal (197, 198). Accordingly, mock infected
monocytes which successfully differentiated into DCs had retained very little enzymatic
activity as compared to the substantial staining in live influenza infected monocytes. UVinactivated virus infected monocytes, again, showed an intermediate phenotype (Figure
3.13). These results further demonstrated that live influenza virus infected monocytes
failed to attain cytochemical characteristics of fully differentiated DCs.
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An important finding was the ability of influenza virus to affect the antigencapturing capability, the hallmark function of any APC including DCs. Antigen
endocytosis by live influenza infected monocytes were significantly reduced compared
to mock infected cells (Figure 3.14, p <0.05). UV-inactivated virus infected monocytes
showed similar endocytic capability to that of mock samples suggesting that functional
inhibition of monocyte-derived DCs required active viral replication. This effect of
influenza mediated inhibition of endocytosis is far-reaching since this would in turn
prevent infected monocyte derived DCs from presenting the viral antigen to T cells and
thereby blocking any subsequent activation of adaptive immune response.
Next, the mRNA expression of cytokines that are known to influence monocyte
differentiation into dendritic cell was studied. IL-10 which is an anti-inflammatory and
immunosuppressive cytokine which was synthesized at increased levels both in UVinactivated and live influenza infected cells compared to mock infected monocytes
(Figure 3.15). On the contrary, production of IL-12, an inflammatory cytokine, was
higher in mock samples than in live influenza infected monocytes. TGF-ß also followed a
similar pattern as of IL-12. Now, it is known that IL-10 inhibits development of DCs from
monocytes while IL-12 and TGF-ß favors the differentiation process (168, 199).
Additionally, differentiated DCs produce large amounts of IL-12 that in turn drive CD4+ T
cells towards a Th1 type immune response which is necessary for clearance of influenza
virus infection (200, 201). On the other hand, IL-10 has a detrimental effect on the host
immune response and subsequent recovery from influenza infection (202). It also
increases susceptibility to secondary bacterial infections (203). These results showed
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that influenza virus infection of monocytes resulted in production of a coordinated
cytokine profile that not only inhibited DC differentiation but also prevented
development of a Th1 type immune response and recovery from virus infection.
These conclusions were further extended to include the other subtype (H3N8) of
equine influenza virus and to address the possibility of a virus subtype specific
inhibition. Since influenza virus NS1 protein has an established immune antagonistic
activity and is also known to inhibit maturation of DCs (section 2.2.8, chapter I), an NS1truncated virus was used to evaluate the role of this viral protein in this inhibition
process. As evidenced in Figure 3.16, both the wild type virus (KY/02) and its NS1defective variant inhibited phenotypic expression of DC surface markers. Both viruses
were also able to block antigen endocytosis by infected monocytes (Figure 3.17). Since
the NS1-truncated virus (NS 1 -73 a.a.), although lacks the effector domain but retains
the RNA-binding domain (section 2.2.8), it is possible that only the RNA-binding domain
was sufficient for the viral inhibition of DC differentiation. However, it is particularly
important to note that the inhibition by NS1-defective variant was more enhanced than
the wild type virus (Figure 3.16). This data not only proved that completely functional
NS1 protein was not necessary for influenza virus mediated inhibition of monocyte
differentiation, but also indicated to a possible mechanism of this viral inhibition. IFNα/ß, when added to the culture media, have been shown to exhibit a negative
regulatory effect on differentiation of fully functional DCs from monocytes (204). In
these experiments also, NS1-truncated influenza virus infected monocytes synthesized
more IFN-α mRNA than the wild type virus (Figure 3.18). Although no direct co-relation
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could be established here, IFN-α produced by infected monocytes can act in an
autocrine negative-feedback mechanism to inhibit their development into DCs.
Nonetheless, these results demonstrated that the viral inhibition of monocyte
differentiation is not specific for the H7N7 subtype as H3N8 subtype was also able to
block DC development. It further showed that influenza virus can inhibit monocyte
differentiation into DC independent of complete NS1 protein activity.
Although the heterogeneity of monocyte-derived DCs makes their precise
characterization very intricate, experiments in this dissertation provided a general
insight into the effects of influenza virus infection of monocytes that are cultured in
vitro for differentiation into DCs. These experiments, taken together, demonstrated that
equine influenza virus could successfully infect and transcribe its genomic RNA in GMCSF and IL-4 pre-treated monocytes, although an early inhibition of viral protein
synthesis prevented efficient progeny virus production. It also showed that infection
with influenza virus prevented monocytes from differentiating into DCs. Although UVinactivated virus imposed a partial inhibition, complete morphological and functional
inhibition required at least limited viral replication. The mechanism of this inhibition,
although unconfirmed in this dissertation, possibly involves TLR-mediated activation of
cytokine (e.g. IFNs) productions. Since DCs are critical in initiating immune responses
against viral infections, this inhibitory effect of influenza virus would block an early
development of virus specific immune activation. For an acute infection like influenza,
this will provide ample opportunities to the virus for efficient replication and
transmission to other susceptible hosts. So, the experiments described in this
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dissertation identify a new strategy by influenza virus to stall activation of an innate and
subsequent adaptive immune response and thereby evade an anti-viral immunity.
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Future research prospect
Findings of this dissertation research have shown that influenza virus infection of
blood monocytes can inhibit their differentiation into DCs and have alluded to possible
mechanism of this inhibition. However, the precise mode of this viral inhibition remains
to be ascertained. It needs to be determined whether activation of TLR pathways plays
any role in this process and if it does, which TLR in particular is resdponsible.
Additionally, although it has been shown in this dissertation that activity of fully
functional NS1 protein is not necessary for the viral inhibition, roles of other viral
proteins such as HA and NA are yet to be defined. This offers an interesting avenue of
future research.
Since at least a proportion of DCs develop from blood monocytes and influenza
virus infection of monocytes inhibited their development into DCs; this would impair
proper immune activation and thereby exacerbate the disease condition or delay
recovery. Revelation of the molecular mechanism of this inhibition would be important
because that knowledge can be further employed for improvement of vaccines.
Prospects of different vaccine adjuvant which may help monocytes overcome virus
mediated inhibition of DC differentiation could be investigated.
The results described in this dissertation may also serve as the basis for further
research to better understand influenza virus replication as well as improvements of
vaccines. Since only GM-CSF pre-treated monocytes are known to be permissive for
influenza infection and the experiments here showed that GM-CSF and IL-4 pretreatment inhibited viral replication, particularly at the stage of viral protein synthesis;
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advanced research could be carried out to elucidate the precise molecular mechanism
of this inhibition. Development of monocytes towards DCs may stimulate gene
transcription and expression of cellular proteins (that may not be activated in
macrophages) which may block viral protein synthesis. Such discoveries may lead to
development of novel anti-viral drugs.
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